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ABSTRACT
Signaling Pathways Involved in Regulation of Glucose-6-Phosphate
Dehydrogenase (G6PD) by Arachidonic Acid
Indrani Talukdar
Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme of
pentose phosphate pathway and provides NADPH for de novo fatty acid biosynthesis. For
the later reason, G6PD is known as a lipogenic enzyme. Insulin induces expression of
G6PD mRNA via activating the PI3 kinase pathway in primary rat hepatocytes. Addition
of arachidonic acid, a polyunsaturated fatty acid, in the medium interferes with the PI3
kinase pathway, and thus inhibits the insulin-mediated induction of G6PD. Arachidonic
acid in the presence of insulin induces p38 MAP kinase pathway over insulin treatment
alone. Activation of p38 MAP kinase by arachidonic acid interferes with the insulin
signal transduction pathway by phosphorylating IRS-1 at Ser-307 and preventing PI3
kinase activation and Akt-phosphorylation. Inhibition of the p38 MAP kinase pathway by
using a specific inhibitor, SB203580, attenuates the inhibitory effect of arachidonic acid
on G6PD and at the same time reverses its effect on IRS-1 and Akt-phosphorylation.
Arachidonic acid also activates AMP-activated protein kinase (AMPK) in primary
rat hepatocytes by phosphorylating it at Thr-172. Activators of AMPK, AICAR and
metformin inhibit the induction of G6PD mRNA by insulin. AICAR induces
phosphorylation of p38 MAP kinase in primary rat hepatocytes. AICAR-mediated
inhibition of G6PD mRNA expression is dependent on the activation of the p38 MAP
kinase pathway, as in the presence of the p38 MAP kinase inhibitor the inhibitory effect
of AICAR on G6PD mRNA expression is abolished. AICAR also interferes with PI3
kinase pathway by inducing Ser-307 phosphorylation of IRS-1 and inhibiting Akt
phosphorylation. Thus, this AMPK activator mimics the effect of arachidonic acid both
on insulin signaling pathway and on G6PD mRNA expression.
Activation of the mammalian target of rapamycin (mTOR) pathway by insulin is
required for the insulin-mediated induction of G6PD mRNA expression. Arachidonic
acid inhibits the phosphorylation of the downstream effector protein of mTOR, S6K-1 at
Thr-389 which suggests it interferes with activation of mTOR. This provides an indirect
evidence of the activation of AMPK by arachidonic acid in primary rat hepatocytes, as
activation of AMPK results in the inhibition of mTOR/S6K-1 pathway. However,
inhibition of mTOR, rather than activation, rules out the possibility of involvement of this
pathway in the interference of the PI3 kinase activation upon arachidonic acid treatment.
We also have ruled out the possibility of involvement of protein kinase C (PKC), as
neither activators of PKC mimic the action of arachidonic acid on G6PD nor inhibitors of
PKC can abolish the effect of arachidonic acid on G6PD mRNA expression.
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1Chapter 1
Introduction
G6PD-Its cellular role
Glucose-6-phosphate dehydrogenase (G6PD) is the first and the rate-limiting
enzyme in the pentose phosphate pathway. This enzyme oxidizes glucose-6-phosphate
into 6-phosphogluconate, and produces NADPH, the major source of reducing
equivalents that cells need for protection against reactive oxidation species. G6PD, along
with 6-phosphogluconate dehydrogenase provide 50% of the NADPH essential for de
novo fatty acid biosynthesis in liver and adipose tissue and thus is considered to be a
lipogenic enzyme.
G6PD is the only enzyme that makes NADPH in erythrocytes and thus helps in
maintaining the reduced state of glutathione. Deficiency of G6PD makes the erythrocytes
prone to oxidative damage. Induction of G6PD expression due to oxidative stress has
been observed in many cell types (162, 198). Incubation of rat hepatocytes with
acetaldehyde or ethanol also increases expression of G6PD (102, 177, 183). A genetic
deficiency of G6PD is associated with hemolytic anemia in response to consumption of
fava beans, viral illnesses, and drugs such as antimalarial agents, sulfonamide antibiotics,
nonsteroidal anti-inflammatory agents, and even aspirin. Point mutations within the
coding region of the gene results in a relative decrease in G6PD enzyme activity (201).
G6PD-deficient individuals are also hypolipidemic, displaying both decreased serum
cholesterol and triacylglycerol concentration (118, 166), underscoring the importance of
G6PD activity for reductive biosynthetic reactions.
The structure of the G6PD gene
The G6PD gene in humans, mice, and rats is located on the X chromosome (xq
228), spans 18.5 kb, and contains 13 exons and 12 introns (121, 195). The protein
produced from the mRNA is about 59 kDa and consists of two to four subunits per
molecule and thus forms a homodimer or a homotetramer of the active enzyme (150).
The G6PD promoter is embedded in a CpG island that is conserved between mice, rats
and humans (121, 195). The promoter of G6PD contains a TATA-like element and
numerous stimulatory protein 1 (Sp1) elements, but no CAAT element (121, 151, 154,
195). The translational start site of G6PD is located in exon 2 and has been mapped in
mice, rats, and humans (55, 84, 121, 189). The number of introns and exons is also
conserved and the sequence identity is 87% between the mouse cDNA and the human
cDNA. The sizes of the mRNA in mice, rats and humans are 2341 bp, 2319 bp, and 2167
bp respectively. There are some unique characteristics about the G6PD gene. The second
intron is about 11 kb, which accounts for over half the size of the gene. The size of exon
13 is very large (811 nucleotides); the 3’untranslated region (3’UTR) is also large (720
nucleotides) and contains one polyadenylation site (5).
Regulation of G6PD by hormonal and nutritional factors
While G6PD enzyme activity is expressed in all cells, its synthesis is regulated
only in liver and adipose tissue in response to diet and hormones. Consistent with other
lipogenic enzymes, prolonged starvation decreases G6PD activity, whereas, G6PD
activity as well as mRNA accumulation is induced several fold in the livers of intact
animals fed a fat-free, high-carbohydrate diet after starvation (81, 175).
G6PD gene regulation by nutritional factors:
Consumption of a fat-free, high-carbohydrate diet, containing glucose or fructose,
causes the largest increase in G6PD enzyme activity. The effect of fructose is greater than
glucose and feeding intact animals a diet containing starch as a source of carbohydrate
does not show as great an effect (56, 98). Primary rat hepatocytes incubated with 0-25
mM glucose also show increasing amounts of G6PD activity (161). A similar effect was
3observed when HepG2 cells were incubated with various concentrations of glucose.
Enhanced accumulation of G6PD mRNA was found within 12 h with as low as 1mM
glucose, and a maximum 5-fold induction was observed with 25 mM glucose (B.Griffith
and L. Salati, unpublished). Other lipogenic and glycolytic genes such as malic enzyme,
spot14, and pyruvate kinase are also regulated by monosaccharides. The regulatory factor
for the carbohydrate stimulation of these genes is thought to be an intermediate in the
metabolism of glucose and fructose (68, 196).
In contrast to the stimulatory effect of a high-carbohydrate diet, G6PD activity
and mRNA accumulation are decreased in animals fed a diet rich in polyunsaturated fatty
acid (PUFA) (39, 40, 99, 175). In the presence of similar carbohydrate intake, the
addition of linoleate (18:2), or linolenate (18:3) in the diet decreases the activity of G6PD
in rats (38). At the same time, arachidonic acid (20:4) or eicosapentanoic acid (20:5)
inhibit G6PD gene expression in rat hepatocytes (161, 176, 213). Addition of saturated
fatty acids to the diet such as palmitate (16:0), and stearate (18:0), and monounsaturated
fatty acids such as oleate (18:1), do not inhibit G6PD activity (38, 40). Similarly,
saturated or monounsaturated fatty acids do not inhibit G6PD gene expression in primary
rat hepatocytes. The inhibitory effect of dietary PUFA on G6PD is specifically observed
in liver. The diet containing PUFA does not inhibit G6PD gene expression in adipose
tissue (39).
G6PD gene regulation by hormonal factors:
The effect of starvation and refeeding on G6PD gene expression suggests a role
for insulin and glucagon in the regulation of this gene (122). Streptozotocin-treated rats
whose pancreatic b-cells are destroyed and thus insulin secretion is abolished, are not
capable of inducing G6PD activity upon refeeding (14). In diabetic rats, the increase in
G6PD activity upon refeeding is attenuated in both liver and adipocytes, which is restored
upon insulin replacement therapy (15, 67, 69). Glucagon and cyclic AMP prevent the
induction of G6PD upon fasting/refeeding of intact animals (63).
4G6PD is also regulated by thyroid hormone and glucocorticoids. Thyroidectomy decreases
G6PD expression, which is restored upon treatment with thyroid hormone. 2,2', 5’-triiodo-L-
thyronine (T3), the active form of thyroid hormone, induces G6PD expression in hypothyroid rats
without involving an increase in G6PD mRNA (58). However, upon T3 administration, G6PD
activity is induced 2-fold in hyperthyroid rats and this parallels the mRNA abundance (126).
Adrenalectomized rats do not induce G6PD gene expression upon refeeding (14). Glucocorticoids
by themselves do not have a significant effect but they amplify the insulin stimulation of G6PD
(183).
G6PD regulation by hormonal factors is also observed in primary rat hepatocytes
in culture. Incubation of rat hepatocytes with insulin results in a 3- to 4-fold increase in
G6PD activity and mRNA abundance (108, 161, 176, 228). Glucocorticoids also
positively regulate G6PD gene expression. Glucocorticoids and insulin show additive
effect on G6PD (183). Unlike in intact animals, T3 and glucagon do not show any effect
on G6PD mRNA expression in cultured hepatocytes (134, 228).
Humoral factors are not involved in transcriptional regulation of G6PD.
In sharp contrast to the regulation of other lipogenic enzymes, starvation,
refeeding, insulin, or high dietary fat do not regulate the transcriptional activity of the
G6PD (85, 175, 176). No difference in the rate of transcription of the gene was observed
with nuclear run-on assays with liver nuclei of mice or rats, either starved or refed with
high-carbohydrate diet, or fed with low- or high-fat diets. Whereas, transcription of fatty
acid synthase (FAS) and stearoyl-CoA desaturase (SCD), two other lipogenic enzymes
regulated by PUFA, was decreased 70% in animals fed a high-fat diet (175). Starvation
and refeeding induced transcription of these two genes 65-and 19-fold respectively.
Incubation of rat hepatocytes with insulin, glucose and arachidonic acid likewise did not
change the rate of transcription of G6PD, however, a similar treatment with insulin
decreased the rate of transcription of phosphoenolpyruvate carboxykinase (PEPCK)
indicating that insulin was active in this system (176).
5Posttranscriptional regulation of G6PD
A lack of change in the rate of transcription by different dietary factors raised the
possibility of posttranscriptional regulation of the G6PD mRNA. Genes transcribed into
pre-mRNA are processed before they are released into the cytoplasmic pool of mature
mRNA. The processing of pre-mRNA involves 5’ capping, 3’ polyadenylation and
splicing of introns. Any of these steps could be involved in post-transcriptional
regulation.
Comparing the abundance of G6PD mRNA in different cellular fractions in
starved and refed mice and mice fed a high-fat diet, it was confirmed that post-
transcriptional regulation of G6PD occurs inside the nucleus (85). Refeeding starved
mice resulted in a 18-fold increase in cytoplasmic mRNA abundance and a 13-fold
increase in G6PD mRNA in the nucleus. This suggested that regulation of G6PD in this
dietary paradigm occurred primarily in the nucleus. Moreover, the change in G6PD
mRNA abundance in the cytoplasm was parallel to that in the nucleus, which confirmed
that nucleocytoplasmic transport of the mature mRNA was not regulated.
Inhibition of G6PD expression by dietary PUFA also involves a nuclear step. In
the livers of mice fed a high-fat diet compared to animals fed a low-fat diet, accumulation
of G6PD mRNA in the nucleus was inhibited 60-70%. Inhibition of G6PD in total RNA,
which is more representative of cytoplasmic RNA, paralleled the inhibition seen in the
nucleus (85). Similar results were observed in primary rat hepatocytes incubated with
arachidonic acid to inhibit the insulin- and glucose-mediated induction of G6PD (175).
Incubation of rat hepatocytes with arachidonic acid caused about 50% inhibition of
cytoplasmic mRNA abundance and about 60% inhibition of nuclear mRNA abundance,
mimicking the above results in the intact animals. Because changes in the amount of
G6PD mRNA occur in the nucleus and precede the changes in amount of G6PD mRNA
6in the cytoplasm, steps involved in processing of the nascent G6PD transcript, that is
splicing, and/or polyadenylation, may be sites of regulation.
Regulated splicing of pre-mRNA in the nucleus
In all eukaryotic cells the primary transcript of the gene or the pre-mRNA is
processed into mature mRNA inside the nucleus before it moves to the cytoplasm for
protein translation. Splicing of introns of the pre-mRNA is one of the most important
processing steps in all eukaryotes. Splicing involves the recognition of the exon-intron
boundaries by various splicing factors known as small ribonuclear proteins or snRNPs.
Binding of various snRNPs to the pre-mRNA produces multicomponent complexes
known as spliceosomes. Different snRNPs recognize different consensus sequences
present in the introns. For example, U1 snRNP recognizes a consensus GU sequence at
the 5’ splice junction, whereas U2 snRNP binds at the branch point site, a consensus
sequence of YNYRAY (Y is pyrimidine and R is purine base). U2 snRNP auxiliary
factor 65 and 35 (U2AF 65 and 35 respectively), also known as non-snRNP splicing
factors, bind at the polypyrimidine tract and at the 3’ splice junction with a consensus AG
sequence respectively in the introns. A tri-snRNP complex known as U4/U6.U5 finally
binds to the pre-mRNA, which, after a vast rearrangement, brings the two adjacent exons
into closer proximity and the splicing of the intervening intron takes place. Two adjacent
exons are finally ligated after two trans-esterification reactions (107).
Regulated splicing often involves splicing co-activators and/or co-repressors in
the nucleus in addition to the snRNPs. Splicing co-activators are typically members of the
SR (RNA binding proteins composed of an RNA recognition motif and a serine (S) and
arginine (R) rich domain) family of proteins whereas splicing co-repressors belong to the
hnRNP (heterogeneous nuclear ribonucleoprotein) family. The SR protein binding site in
an exon is known as the exonic splicing enhancer (ESE) sequence (17, 71) whereas
hnRNP-binding site in an exon is known as exonic splicing silencer (ESS) sequence (117,
171, 203). Recognition of ESE sequences by SR proteins efficiently recruits U2 snRNP at
7the branch point and also U2AF 65 and 35 at their corresponding binding sites (31). ESE
and ESS sequences could be localized on separate exons or could be juxtaposed on the
same exon. In the later case, a competition between the SR and the hnRNP proteins takes
place for binding. Recruitment of hnRNP proteins in an exon thus, inhibits the binding of
SR proteins and in turn, interferes with the recruitment of snRNPs and an inhibition of
splicing takes place.
Both the SR and hnRNP proteins are regulated by phosphorylation and
dephosphorylation (66, 106, 217, 230). Phosphorylation/dephosphorylation of these
proteins change their localization in various compartments in the nucleus and/or
facilitates the nuclear-cytoplasmic shuttling of the protein.
Phosphorylation/dephosphorylation of these proteins may also change their binding
affinity for other interacting proteins or the affinity for the RNA (217, 225). Depending
on the availability of these proteins in the activated form in the nucleus, SR or hnRNP
binds, and an induction or repression of splicing takes place.
Most studies of regulated splicing have focused on alternative exon inclusion; that
is, depending on various conditions, one or a group of exons are either excluded or
included during formation of a mature mRNA from a primary transcript. G6PD mRNA is
not alternatively spliced, however, the constitutive splicing of this mRNA is regulated;
that is, under all conditions, all of the 13 exons of G6PD are spliced but the efficiency of
this splicing event varies under different hormonal and nutritional status (5, 191). There
are only few examples where humoral factors regulate splicing efficiency of
constitutively spliced exons. Diverse mechanisms appear to be involved in this type of
post-transcriptional regulation. For example, regulated expression of thymidylate
synthase during the cell cycle requires its promoter and a spliceable intron but is not
specific to any intron of the mRNA (100). Splicing of the tumor necrosis factor-alpha
(TNF-alpha) mRNA requires a cis-acting element in the 3’-UTR of the transcript (140).
Dietary carbohydrate, refeeding and insulin enhance the stability of the pre-mRNA of the
single intron of spot-14 mRNA (5, 26, 205). Spot-14 is a protein involved in lipid
metabolism. Splicing is the postulated mechanism for the regulation of Spot-14, however,
8further characterization and molecular details involved in this regulation have not been
reported yet.
Regulation of alternative splicing is better characterized, however, involvement of
various signal transduction pathways in alternative splicing is a relatively new area to
explore. As regulation of alternative splicing involves phosphorylation/dephosphorylation
events of the SR/hnRNP proteins, involvement of different signaling pathways that
activate various kinases/phosphatases is not surprising. Insulin-mediated activation of the
phosphoinositide 3-kinase (PI3 kinase) pathway regulates splicing of exon bII of protein
kinase C (PKC) b involving phosphorylation of the SR protein SRp40 (146, 147).
Activation of the Erk mitogen-activated protein kinase (MAP kinase) pathway, PKC and
Ras are involved in splicing of exon v5 of CD44 and exons 4-6 of CD45 (105, 208).
Activation of p38 MAP kinase and its upstream effector MAP kinase kinase (MKK) 3/6
by osmotic shock or UV irradiation has been shown to modulate sub-cellular distribution
of hnRNP A1, which in turn regulates alternative splicing of adenovirus E1A pre-mRNA
reporter construct (199). Involvement of signaling pathways in regulation of constitutive
splicing has not yet been explored. Regulation of G6PD gene expression is mediated via
the PI3 kinase and MAP kinase pathways (discussed in chapters 2 and 3). Involvement of
these signaling pathways in the regulation of constitutive splicing of G6PD mRNA would
be a novel finding.
When an mRNA is not spliced efficiently or polyadenylated, it is degraded by one
of two different pathways inside the cell nucleus. In the first pathway, RNA that is not
completely processed does not leave the site of transcription in the nucleus (16). Specific
proteins recruited by the spliceosome, most likely mark correct splicing and initiate the
export of the RNA to the cytoplasm. Lack of splicing does leave these marks and the
RNA is not exported, but degraded in the nucleus. In yeast and mammalian cells, the
degradation is catalyzed by a complex of exonucleolytic enzymes called the nuclear
exosomes (16, 127, 128). Several questions like how in a multi-intron transcript the
correct and complete splicing of all introns are detected or what proteins or signals are
responsible to recruit the exosomes to a mRNA, remain to be answered.
9The second pathway of nuclear RNA degradation is due to the presence of the
premature stop codons in the RNA transcript. This decay pathway appears to need either
the presence of a Kozak consensus sequence or an internal ribosomal entry site in the
RNA (206). Some components of the translational machinery may act as a scanner and
detect the premature termination codon and target the mRNA for degradation (13, 127,
159). G6PD mRNA does not contain premature termination codons, but inefficiently
spliced pre-mRNA, which retains one or more introns, can give the appearance of an
mRNA containing premature stop codons. Whether nuclear exosomes are responsible in
this pathway too, is not known.
Splicing of G6PD pre-mRNA is the regulatory step
To investigate whether splicing of G6PD pre-mRNA is the regulatory step in the
post-transcriptional regulation of G6PD, different nuclear fractions were isolated from
the livers of mice that had been starved and then refed a high-carbohydrate diet. The
insoluble nuclear fraction contains pre-mRNAs that are both newly synthesized and are
undergoing processing whereas the nuclear membrane fraction contains mature mRNA
(35, 52). Two probes containing different exon-intron boundaries of G6PD were used in
RNase protection assay to quantify and compare the amounts of unspliced and spliced
RNA in the livers of starved and high-carbohydrate refed mice. During refeeding, the rate
of accumulation of spliced RNA significantly increased over the unspliced RNA (5). To
further confirm that the regulation occurs at the level of splicing, RNase protection assays
were performed using a probe that crosses multiple splice junctions (exon8-intron8-
exon9-intron9) (5). The different protected fragments detected in the insoluble nuclear
fractions of starved and refed mice liver were unspliced (exon8-intron8-exon9-intron9),
partially-spliced (exon8-exon9-intron9) and fully-spliced RNA. Refeeding caused a
greater accumulation of partially-spliced and fully-spliced RNA compared to the starved
mice. At the same time, the ratio of partially-spliced RNA to unspliced pre-mRNA and
the ratio of fully-spliced RNA to the unspliced pre-mRNA increased when the starved
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mice were refed with a high-carbohydrate diet. These results confirmed that the
regulation of splicing was an early process inside the nucleus. Similar results were
obtained in mice fed with a low-fat vs. a high-fat diet.  The low-fat diet caused a greater
accumulation of spliced mRNA compared to the high-fat diet (5).
Polyadenylation of G6PD is not a regulatory step.
Improper 3’ end formation of the pre-mRNA can cause enhanced degradation of
the transcript.  To test whether this phenomenon is associated with the dietary regulation
of the G6PD gene, the length of the poly (A) tail of the mRNA was measured by an
RNase H assay on mRNA from the nuclear insoluble fraction of livers from starved and
refed mice. It was found that, despite large changes in overall mRNA accumulation, the
length of the poly (A) tail remained the same in both dietary conditions (5). Similarly, the
inhibition of G6PD reporter RNA in hepatocytes incubated with arachidonic acid was
also independent of the polyadenylation signal present in the construct (191).
Exon 12 of G6PD contains the cis-acting element for PUFA-
mediated regulation
All of the results indicating regulated splicing of G6PD mRNA raised the
question of whether a specific RNA sequence is responsible for the regulated splicing. To
investigate this, different pre-mRNA reporter constructs representing subsets of the 18-kb
gene, were made and transfected into primary hepatocytes (191). Transcription of these
reporter constructs was driven by the CMV promoter. Expression of RNA from a reporter
construct containing intron 6 through the 3’UTR (pCMV7-13 3’UTR) of G6PD was
inhibited by 50% when cells were treated with insulin and arachidonic acid, compared to
cells treated with insulin alone, and the endogenous G6PD gene expression in rat liver
was attenuated to the same extent. Reporter constructs containing sequences upstream of
intron 6 ligated to the 3’UTR were not regulated by arachidonic acid. Replacing the
CMV promoter with G6PD promoter in these reporter constructs did not change the
result, indicating that the effect of arachidonic acid was not promoter specific. Expression
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of b-actin mRNA was not affected by arachidonic acid, showing that PUFA specifically
regulates G6PD RNA expression and it is not a generalized effect.  These results
confirmed that the regulation of G6PD expression requires an RNA sequence located
somewhere between intron 6 and the 3’UTR of G6PD pre-mRNA.
To further define the RNA sequence regulating mRNA splicing of G6PD,
successive 5’ deletions of the reporter construct pCMV7-13 3’UTR were done and the
new constructs were transiently transfected into primary rat hepatocytes (191). The
amount of reporter RNA was decreased in the presence of arachidonic acid in all
constructs containing sequences between the start of exon 12 to the 3’ end of the gene.
Furthermore, this region of the gene was able to confer inhibition by arachidonic acid
onto a heterologous RNA, b-galactosidase, which by itself is not regulated by arachidonic
acid. Deletion of exon 12 from the reporter construct abrogated the inhibition by
arachidonic acid. Thus, it was confirmed, that exon 12 contains a cis-acting element
involved in inhibition of G6PD RNA accumulation by arachidonic acid.
This idea was further supported when mice fed a high-fat diet had a much higher
accumulation of partially-spliced RNA containing intron 11 compared to the low-fat diet
fed mice. At the same time, the high-fat diet caused a 61% inhibition of the accumulation
of the fully-spliced RNA. This data indicated that high-fat diet might inhibit the splicing
of intron 11. The retention of pre-mRNA with this intron in the nucleus subsequently
would result in the degradation of the incompletely spliced RNA (191). These data,
together, confirmed that the posttranscriptional regulation of G6PD by a high-fat diet or
arachidonic acid takes place at the level of splicing in the nucleus and the potential cis-
acting element for this regulation is located within exon 12 of G6PD mRNA.
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Insulin signaling.
Insulin is a major signaling molecule in intermediary metabolism. Carbohydrate
and lipid metabolism are regulated by insulin in various tissues, including liver, muscle,
brain and adipocytes. Insulin is secreted from the pancreatic beta cells in response to
consumption of dietary carbohydrate. Upon secretion, the primary role of insulin is to
maintain blood glucose level. Insulin helps to mobilize glucose transporters (like GLUT
4), to the plasma membrane of skeletal muscle and adipose tissue so that blood glucose
can be internalized by these tissues. Insulin increases the activity of the glycolytic and
lipogenic enzymes whereas it inhibits gluconeogenesis in various organs. Regulation of
genes involved in carbohydrate and lipid metabolism by insulin also helps to maintain
blood glucose concentration. Upon secretion, insulin binds to the insulin receptor on the
cell membrane and activates the insulin signaling. For regulation of energy homeostasis
and intermediary metabolism, insulin signaling through the PI3 kinase pathway is most
important for its regulatory properties (169). G6PD is highly regulated by insulin and
inhibition of the PI3 kinase pathway abolishes the insulin-mediated induction of G6PD in
primary rat hepatocytes (202).
Here I am discussing, in brief, the PI3 kinase pathway, highlighting certain
proteins in this pathway such as the insulin receptor, insulin receptor substrates (IRS),
PI3 kinase and the down stream effector protein Akt/PKB.
Insulin receptor.
The insulin receptor is a trans-membrane receptor and belongs to the receptor
tyrosine kinase family. It is composed of two alpha and two beta subunits that are linked
via disulfide bonds. The alpha subunits are in the extracellular domain and bind insulin,
whereas the beta subunits span the membrane and contain the ATP binding and tyrosine
kinase domains. Upon binding to insulin, the beta subunits trans autophosphorylate each
other on tyrosine residues via their kinase domain. Tyr-phosphorylation of the insulin
receptor activates the receptor, which in turn binds to the downstream protein IRS in the
signaling cascade. Recognition and binding of the IRS molecules to the insulin receptor is
the required step towards the activation of the PI3 kinase pathway.
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IRS proteins.
The downstream effector molecule of the insulin receptor is IRS. IRS proteins act
as mediators for the activation of PI3 kinase via insulin. Four members of IRS proteins
have been identified and are named as IRS-1-4 (187, 188). IRS-1 and –2 are widely
distributed in mammalian tissues, IRS-3 is found in adipose tissue, fibroblasts and in liver
cells, IRS-4 is found in embryonic kidney cells. All family members of IRS proteins
contain N-terminal pleckstrin homology (PH) domain and phospho-tyrosine-binding
domain (PTB) (169). The PTB domain binds directly to the insulin and insulin-like
growth factor-1 (IGF-I) receptors at the Tyr-phosphorylated NPEY motif. The PH
domain of IRS-1 is necessary for the association with the receptor and it also mediates
the association of IRS-1 with membrane-bound phosphoinositides (226). The IRS
proteins contain multiple tyrosine phosphorylation sites like YMxM and YxxM motifs.
The tyrosine in the YMxM motif is the target for phosphorylation by the insulin receptor
kinase (170). Other tyrosine phosphorylation sites of IRS-1 are recognized by various
adaptor proteins like growth factor receptor-bound protein 2 (Grb2), Nck, Crk,
tyrosine–phosphatases like SHP2 and tyrosine kinases like Fyn etc (227). IRS proteins
are also phosphorylated at tyrosine residues by JAK family associated tyrosine kinase
receptors for growth hormone and various cytokines, however; IRS proteins are not
substrates for epidermal growth factor (EGF)-receptor, or platelet-derived growth factor
(PDGF)-receptor tyrosine kinases (188, 207). Tyrosine phosphorylation at various
residues of IRS-1 by different stimuli can cause diverse signaling responses.
 There is some degree of functional overlap between IRS-1 and –2. IRS-1
knockout mice are only mildly insulin resistant, suggesting that IRS-2 is capable of
substituting for IRS-1, in the insulin signal transduction pathway. In fibroblast cell lines
derived from IRS-1 knock out mice, activation of the PI3 kinase pathway could be
restored to same degree by retrovirus-mediated expression of IRS-1 or IRS-2 (24);
however, functional overlap between IRS-1 and -2 is not total. Targeted disruption of the
IRS-2 gene in mice showed that IRS-1 cannot compensate for the loss of IRS-2, as these
mice developed overt diabetes, reflecting a failure of a complementary role for IRS-1
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(212). Activation of IRS proteins is thus absolutely necessary for the activation of the
insulin signal transduction pathway, failure of which leads to the insulin resistance and
inhibition of insulin-mediated regulation of gene expression and impairment of lipid and
glucose homeostasis.
PI3 Kinase
The downstream effector molecule of IRS proteins in the insulin-signaling
pathway is known as PI3 kinase. Activation of this kinase plays the most important role
in mediating the effect of insulin in the intermediary metabolism and gene expression.
Activation of the insulin receptor activates PI3 kinase, which turns on a signaling cascade
further downstream in this pathway. PI3 kinase is responsible for the following
phosphorylation reactions:
1) Conversion of phosphatidylinositol 4,5-bisphosphate, [PI (4,5) P2] (PIP2) into
phosphatidylinositol 3,4,5-trisphosphate, [PI (3,4,5) P3] (PIP3),
2)  Conversion of phosphatidylinositol 4-phosphate, [PI (4) P] into
phosphatidylinositol 3,4-bisphosphate [PI (3,4) P2], and
3) Conversion of phosphatidylinositol (PI) into phosphatidylinositol 3-phosphate
(PI3P).
Conversion of PIP2 into PIP3 is considered the main function of PI3 kinase (179, 181).
There are four classes of PI3 kinases. Class 1a, 1b, 2 and 3. Class 1a PI3 kinase
accounts for the activation of signaling upon insulin stimulation. This class is composed
of an adapter/regulatory subunit and a catalytic subunit (82, 87). Class 1b is regulated by
G-proteins but not by insulin. The catalytic subunit but not the adapter subunit of this
class of PI3 kinase shares significant sequence homology to that of class 1a (180). Class 2
PI3 kinase is widely expressed and is activated by insulin, however; this class of PI3
kinase is incapable of converting PIP2 into PIP3, a key mediator of insulin signaling, and
thus it seems unlikely that this class of PI3 kinase would mediate common insulin
responses (48, 200). Class 3 PI3 kinase can only use PI as its substrate to produce PI3P.
As insulin does not increase the cellular level PI3P, it is unlikely that this class of PI3
kinase will play any role in insulin signaling (41).
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The domain structure of class 1a PI3 kinase is well characterized. The molecular
mass of the catalytic subunit is 110 kDa and there are three highly homologous isoforms
of this subunit known as p110a, p110b and p110d. All of these isoforms contain a PI3
kinase adapter protein binding domain and Ras binding domain at the N-terminus and a
kinase domain at the C-terminus (82, 87). The adapter/regulatory subunit of class 1a PI3
kinase is encoded by at least three genes, which provide homologous products. Two
genes generate products of 85 kDa, known as p85a and p85b. There are three splice
variants of p85a known as p85a1, p55a and p50a. All of these gene products contain
two C-terminal SH2 domains and a p110-binding domain in between the SH2 domains.
The isoforms, p85a, p85b and p85a1 each contain a SH3 domain, a Bcr/Rac GAP
homology domain (BH) and two proline-rich regions (P1 and P2) at the N-terminus. The
p55a and p50a isoforms lack the N-terminal SH3, BH or the proline-rich domains and
instead have short novel sequences at the N-terminus. This is probably due to the fact that
they arise from alternate transcriptional start sites. The p55a is highly expressed in brain
and muscle and the p50a is expressed in brain, muscle, liver and kidney (9, 70, 89). The
variability in structure and expression level of the regulatory subunit of PI3 kinase in
different organs suggests that this kinase might be activated via diverse mechanisms
adding to complexity to the signaling pathway.
The SH2 domains of p85 bind with high selectivity to the phosphorylated YxxM
and YMxM sequences (174). Both of these sequences are tyrosine-phosphorylated in
IRS-1. Upon insulin stimulation, IRS-1 is phosphorylated at its several tyrosine residues,
which are then recognized and bound by the SH2 domains of the PI3 kinase. In vitro
studies show that the insulin receptor phosphorylates IRS-1 on four tyrosine residues in
the YMxM motif (Tyr-608, 628, 939 and 987 in rat IRS-1) and one (Tyr-460) in the
YxxM motif. Deletion of these sites abolishes the ability for binding of IRS-1 to the PI3
kinase (158, 186). Binding of PI3 kinase to IRS-1 directly stimulates its activity. The
simultaneous occupancy of both the SH2 domains of p85 by phospho-tyrosine residues of
IRS-1 efficiently recruits and activates the PI3 kinase. The stable complex formation
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between IRS-1 and PI3 kinase is necessary for the activation of PI3 kinase (141), which
eventually relays the insulin-signal to the downstream effector protein Akt/PKB.
Akt/PKB
The downstream protein of PI3 kinase in insulin signaling pathway is Akt/PKB,
whose activation by insulin gives an indirect measure of the activation of the PI3 kinase
pathway and thus is absolutely required to carry out the function of insulin in the
intermediary metabolism. Akt/PKB is a PH domain containing Ser/Thr kinase that is
largely activated by insulin and various growth factors. There are three isoforms of PKB,
a, b and g. PKB a is the major isoform activated by insulin in muscle, liver and
adipocytes. PKB b is activated in adipocytes in response to insulin signaling, however;
PKB g is only responsive to insulin in cell culture models (205). Activation of the PI3
kinase pathway is both necessary and sufficient for the activation of all isoforms of Akt.
In this regard, Akt activation is abolished by inhibitors of PI3 kinase, the dominant
negative isoforms of the PI3 kinase adapter/regulatory subunit and the mutant insulin
receptor which is unable to activate PI3 kinase (6, 25, 54).
Growth factors and insulin increase activation of Akt/PKB by phosphorylating it.
The phosphorylation sites of PKB a are at Thr-308 at the activation loop and Ser-473 at
the C-terminal hydrophobic tail (3). The kinase responsible for the phosphorylation at
Thr-308 of PKB a has been characterized as phosphoinositide-dependent kinase-1 (PDK-
1). PDK-1 also phosphorylates PKB b at Thr-309 and PKB-g at Thr-305. PDK-1 has a
single PH domain, which binds to PIP3. Upon insulin stimulation PIP3 binds directly to
Akt as well at its N terminal PH domain. Binding of PIP3 to both PDK1 and Akt
eventually recruits both of them to the plasma membrane and this promotes efficient
phosphorylation of Akt at Thr-308 by PDK1 (4, 178). The kinase responsible for the Ser-
473 phosphorylation is only recently identified. The mammalian target of rapamycin
(mTOR)-rictor complex has been shown to be the kinase responsible for the Ser-473
phosphorylation of Akt (164) (discussed in detail later).
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The downstream targets of Akt/PKB share a common phosphorylation site. An
optimal peptide substrate of Akt/PKB has a Ser as the phosphoacceptor site, a bulky
hydrophobic amino acid at +1, a Ser/Thr at –2 and conserved arginine residues at –3 and
–5 positions (138). Some of the common targets of Akt/PKB are, glycogen synthase
kinase 3 (GSK3), 6-phosphofructo-2-kinase, the Forkhead family of transcription factors
including FKHR, and AFX, an upstream kinase in MAP kinase signaling pathway Raf,
mTOR, the endothelial nitric oxide synthase eNOS and the pro-apoptotic protein BAD
(165). Ser-phosphorylation of GSK3 by Akt, inactivates this protein, which leads to
activation of glycogen synthesis (43). The Ser-phosphorylation of transcription factors
FKHR and AFX by Akt also inactivates them, leading to a down regulation of the target
genes (23). Activation of mTOR by Akt leads to protein translation and metabolic gene
regulation (discussed in detail later), whereas, regulation of Raf by Akt mediates a cross
talk between the PI3 kinase and the MAP kinase pathways (234). Thus, it is evident that
the activation of insulin signaling which leads to the activation of Akt regulates various
cellular processes.
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Signaling pathways that interfere with the insulin signal
transduction
Various signaling pathways interfere with the PI3 kinase signaling, which results
in decreased insulin sensitivity or causes insulin resistance. Activation of various MAP
kinases, the target of rapamycin (TOR) pathway and various isoforms of PKC have been
reported to inhibit the PI3 kinase pathway. AMP activated protein kinase (AMPK) is
shown to inhibit lipogenic gene expression and at the same time, modulates the PI3
kinase pathway. Non-esterified fatty acid or high-fat diet containing PUFAs has been
shown to activate some or all of these pathways, which in turn interferes with insulin
signal transduction. In this section I am going to discuss in brief these signal transduction
molecules. A schematic diagram of mechanism of inhibition of PI3 kinase pathway by
these molecules is shown in figure 1 and will be discussed in a separate section.
MAP kinases
MAP kinases are a family of protein kinases, which phosphorylate at specific Ser
and Thr residues of their target proteins. These kinases are highly conserved among the
species and are required to regulate various cellular processes, for example, gene
expression, metabolism, mitosis, cell proliferation and programmed cell death (210).
Phosphorylation/dephosphorylation of MAP kinase target proteins can turn on or off their
activity, which in turn can switch on or off a cellular event. Some of the target proteins
for the MAP kinases include other protein kinases, transcription factors and cytoskeletal
proteins.
MAP kinases themselves are regulated by phosphorylation cascades (156). There
are different MAP kinase kinases (MKKs) that selectively phosphorylate and activate
specific MAP kinases. MKKs are in turn activated and phosphorylated by MKK kinases
(MKKKs). In multi-cellular organisms, three well-characterized subfamilies of MAP
kinases exist. They are known as Erk1/2, c-Jun NH2-terminal kinase/ stress-activated
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protein kinase (JNK/SAPK) and p38 MAP kinases. Each of these MAP kinases has
specific MKKs and MKKKs (92).
Erk1/2
Erk 1 and 2 are widely expressed and are involved in the regulation of cell growth
and proliferation. These two proteins are 43 and 41 kDa respectively and contain more
than 85% sequence identity (20). The relative abundance of Erk 1 and 2 varies depending
on the tissue type. Various stimuli including growth factors, cytokines, virus infection,
ligands for the G-protein coupled receptors, transforming agents and carcinogens activate
them. Upon activation both Erk 1 and 2 are phosphorylated on Tyr and Thr residues in
the activation domain. For both Erk1 and Erk2 the Tyr and Thr residues are separated by
a glutamate residue, forming a TEY activation loop (148).
The upstream MKK that phosphorylates and activates Erk 1/2 is known as MEK.
There are two isoforms of MEK, MEK 1 and 2 and both activate Erk1/2, in vitro (231).
The MKKK that activates and phosphorylates MEK is known as Raf. There are three
different isoforms of Raf, known as A-Raf, B-Raf and Raf-1. Raf-1 is ubiquitously
expressed, B-Raf is mostly expressed in neuronal tissues and A-Raf is found in urogenital
tissue. Most studies have been done on Raf-1. Cellular localization, phosphorylation of
Tyr, Thr and Ser residues, and protein-protein interactions have all been implicated for
the regulation and the activation of Raf-1. Raf-1 is activated by small G protein H-, K-
and N-Ras. The phosphorylation state of Raf-1 is influenced by various protein kinases
like Src, PKC, the p21-activated protein kinase (PAK), and Akt/PKB (129). Various
substrates of Erk 1/2 have been identified, among them the transcription factors cAMP-
response element binding protein (CREBP) and sterol regulatory element binding protein
(SREBP), which are involved in metabolic gene regulation (19, 218). Activation of Erk
interferes with the insulin-signaling pathway (Fig. 1, blue lines), details of which will be
discussed later.
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JNK/SAPK
This subfamily of MAP kinases was first isolated and characterized as the stress-
activated protein kinase and as a binding partner of c-Jun (80). c-Jun is a component of
AP-1 transcriptional complex. JNK phosphorylates c-Jun and enhances its transcriptional
activity. The purified JNK proteins are 46 and 54 kDa (80). There are three isoforms of
JNK known as JNK 1, 2 and 3 which shares more than 85% sequence identity. All the
JNK/SAPKs are activated upon phosphorylation at Thr and Tyr residues at their active
sites separated by a proline residue, making a TPY activation loop (109). Cytokines,
ligands for G protein-coupled receptors, various forms of stresses, growth factors, and
transforming agents activate this MAP kinase.
The upstream MKKs that activate JNK upon phosphorylation are known as
MKK4 and MKK7. MKK4 is also known as SEK1, MEK4, JNKK1 and SKK1.
Synonyms for MKK7 are MEK7, JNKK2 and SKK4. MKK4 and 7 preferentially
phosphorylate the Tyr and the Thr residues in the TPY activation loop (111, 224).
Regulation of the JNK pathway is influenced by many MKKKs. There are 13 different
MKKKs that can regulate JNK that allows a wide range of stimuli to activate this MAP
kinase (149). Activation of this MAP kinase causes impairment of insulin signal
transduction pathway (Fig. 1, blue lines), which leads to insulin resistance in diabetes and
obesity. Details of these mechanisms will be discussed later.
p38 MAP kinase
p38 MAP kinase is a 38-kDa-protein member of the MAP kinase family. There
are four subfamilies of p38 MAP kinase, a, b, g and d. The p38 MAP kinase a and b
genes are ubiquitously expressed; however, p38 MAP kinase g and d are expressed
differentially in various tissues. p38 MAP kinase g is predominantly expressed in skeletal
muscle, and p38 MAP kinase d is expressed in lung, kidney, testis, pancreas and small
intestine. These p38 MAP kinase isoforms have 60% sequence identity within the group,
but only 40-45% to the other MAP kinase family members (139).
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p38 MAP kinase is activated by inflammatory cytokines, growth factors, ligands
for G protein-coupled receptors, viruses, stresses, etc (215). The p38 MAP kinases have
Thr and Tyr residues at their active sites separated by a glycine residue, making a TGY
activation loop (72). The upstream kinases that phosphorylate and activate p38 MAP
kinase are known as MKK3 and 6. MKK6 preferentially phosphorylates p38 MAP kinase
a, b, g and d. With the exception of p38 MAP kinase b, all the others are activated by
MKK3. p38 MAP kinase a and d can also be activated by JNK kinase MKK4 and 7 (50,
79, 139, 149).
Further upstream activators known to activate p38 MKK, are diverse, which
explains the fact that p38 MAP kinase can be activated by various stimuli. The known
MKKKs are MTK1, MLK2/MST, MLK3/PTK/SPRK, DLK/MUK/ZPK,
ASK1/MAPKKK5 and TAK1 (139). Different MKKKs function to mediate different
upstream signals. The low molecular weight GTP-binding proteins like Rac and CDC42
are upstream activators of p38 MAP kinase pathway. Rac/CDC42 can directly activate
p38 MKKK via binding with MLK1 and 2. PAK 1, 2 and 3 can be activated upon binding
with Rac/CDC42 and their dominant negative mutants have been shown to inhibit p38
MAP kinase activation (11). Small G protein, Ras, activates p38 MAP kinase as well.
Dominant negative Ras abolishes the interleukin-mediated activation of p38 MAP kinase
while the constitutively active Ras activates this MAP kinase in primary fibroblasts.
Activated Ras associates with TAK1, an MKKK, which activates the p38 MAP kinase
pathway (124, 144).
The first identified substrate of p38 MAP kinase a is MAP kinase-activated
protein kinase 2 (MAPKAP 2). In vivo activation of this kinase is inhibited by a specific
inhibitor of p38 MAP kinase a and b, SB203580 (57). The other downstream substrate,
which was identified subsequently, was MAPKAP 3. MAPKAP 2/3 are known to
activate heat shock protein 27 (HSP 27), cAMP response binding protein (CREB),
activating transcription factor –1 (ATF1) etc (182, 190). Other protein kinases which
have recently been found as downstream substrates for p38 MAP kinase a and b are,
MAP kinase interaction protein kinase, MNK1 (known to bind with translation initiation
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factor eIF-4E), p38 MAP kinase regulated/activated kinase, PRAK (a stress activated
kinase), mitogen- and stress-activated kinase, MSK etc. Some transcription factors are
also phosphorylated and activated by p38 a, for example, ATF-2, ATF-1, CHOP, p53,
C/EBP etc (79, 139, 149).
Activation of p38 MAP kinase pathway has been shown to regulate expression of
various genes. Some of the examples of positive regulation are activation of proliferator
activated receptor g (PPARg) in 3T3L1 adipocytes (49), collagenase 1 and 3 in fibroblasts
(209), cyclooxygenase 2 (COX-2) in Hela and in monocytes (184) and interleukins 1, 6
and 8 in monocytes and macrophages (64). Activation of p38 MAP kinase negatively
regulates Cyclin D1 and low-density lipoprotein (LDL) receptor gene expression in
HepG2 cells (139). A recent report has shown that induction of gluconeogenic genes,
PEPCK and glucose-6-phosphatase (G6Pase), in liver upon fasting is mediated via the
activation of p38 MAP kinase pathway (27). This activation of p38 MAP kinase upon
starvation is mediated via the activation of protein kinase A (PKA). Glucagon, a hormone
secretes during fasting and responsible for the activation of the gluconeogenic genes, is
also capable of activating p38 MAP kinase in primary rat hepatocytes (27). Like Erk and
JNK MAP kinases, activation of p38 MAP kinase also inhibits insulin signaling (Fig. 1,
blue lines), which will be discussed in a later section.
PKC
PKC is a Ser/ Thr kinase and found in all eukaryotes. Depending on the enzyme’s
cofactor requirements, there are three major subgroups of PKC, conventional or cPKC,
novel or nPKC and atypical or aPKC (91). The cPKCs contain a, b, and g isoforms. The
nPKCs have d, e, h, q and m isoforms, and the aPKCs have z, i and l isoforms. All the
PKC isoforms contain a conserved catalytic domain, (also known as the kinase domain),
and a regulatory domain. The conventional isozymes contain a C1 domain that binds to
the diacyl glycerol (DAG) and phorbol esters and a C2 domain that binds to phosphatidyl
serine, which mediates calcium responsiveness at the regulatory site. Thus cPKCs are
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both DAG and calcium sensitive. The nPKCs contain a C1 but a non-functional C2 or
C2-like domain, thus are responsive to DAG but not to calcium. The aPKCs contain
neither a C1, nor a C2 domain and thus are insensitive to both DAG and calcium (91,
125).
The cPKCs and nPKCs are activated by various signaling pathways that activate
phospholipase C (PLC) and produce DAG. For the cPKCs but not the nPKCs, the
recruitment of DAG is calcium dependent. For the aPKCs, the activation takes place in
part via interactions with cdc42-GTP-Par6 complex, which binds to the PB1 domain of
aPKC. Binding to these substrates releases the kinase domain from a pseudo substrate-
binding domain and activates PKC (135, 136). Phosphorylation of PKC is required for its
activation. The phosphorylation takes place at the activation loop that contains TFCGT
motif. Another known phosphorylation site is present near the C terminal hydrophobic
region. PDK 1 catalyzes the phosphorylation event (145).
Activation of various isoforms of PKC can both positively and negatively regulate
insulin-signaling pathway either directly or via activating various MAP kinases (Fig. 1,
red arrows). A discussion in this regard in more detail could be found in a later section.
TOR
Target of rapamycin (TOR) is a Ser/Thr kinase that controls cell growth and
metabolism. Every eukaryotic genome contains a TOR gene. Eukaryotic TORs have a C-
terminal Ser/Thr protein kinase domain, which resembles the catalytic domain of PI3
kinase (216). The mammalian version of TOR is known as mTOR, which forms two
protein complexes mTORC1 and mTORC2. mTORC1 is associated with mTOR, raptor
and GbL (also known as mLST8), whereas mTORC2 is composed of mTOR, rictor and
GbL. An intracellular cofactor peptidyl-prolyl cis/trans isomerase named FKBP12 binds
to rapamycin and inhibits the kinase activity of mTORC1 but not mTORC2; however, the
exact mechanism of this inhibition is not known (73, 103, 163). A small GTPase protein
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Rheb binds directly to the kinase domain of mTOR in mTORC1 and activates the
complex in a GTP-dependent manner. The tuberous sclerosis proteins TSC1 and TSC2
form a heterodimer and inhibit Rheb activation as TSC2 acts as a GAP (GTPase
activating protein), which stimulates GTP hydrolysis of Rheb (Fig. 1), however, the
function of Rheb towards mTORC2 has yet not been established (116).
TOR integrates various signals to regulate cell growth. Insulin and other growth
factors, nutrients, cellular AMP/ATP ratio and stress modulate the mTOR-signaling
pathway. Activation of the PI3 kinase pathway by insulin or growth factors activates Akt.
Akt serves as a negative regulator of TSC1/TSC2 complex (Fig. 1, green lines).
Inactivation of TSC1/TSC2 complex by Akt eventually activates the mTORC1 (Fig. 1)
(119). Excess nutrients, especially amino acids, also can positively regulate this pathway
either indirectly via inhibiting the TSC1/TSC2 complex or directly via activating Rheb
(61, 172). Low cellular energy level increases AMP/ATP ratio that activates AMPK (will
be discussed in detail later). Activated AMPK positively regulates TSC1/TSC2 by
directly phosphorylating and enhancing the GAP activity of TSC2 (Fig. 1, orange line)
(88). Activation of TSC2 in turn inhibits the mTORC1. Cellular stress and hypoxia also
inhibit the mTORC1 complex via activating the TSC1/TSC2 complex (22).
Upon activation, mTORC1 enhances protein translation via activating p70 S6
kinase-1 (S6K-1) and eukaryotic initiation factor binding protein-1 (4EBP-1). S6K-1
requires phosphorylation at two sites for full activation. Thr 389 phosphorylation of the
C-terminal hydrophobic motif by mTORC1 and Thr 229 phosphorylation of the kinase
domain by PDK1 is absolutely required for the activation of S6K-1. Activated S6K-1 in
turn activates 40S ribosomal protein S6 and enhances translation. On the other hand,
mTORC1 enhances cap-dependent translation via phosphorylating 4EBP-1. Upon
phosphorylation, 4EBP-1 releases eIF4E, a eukaryotic translation initiation factor, and
translation initiation takes place. Interaction of mTORC1 with S6K-1 and 4EBP-1 is
mediated through raptor (78, 194).
The mTORC2 complex has only recently been identified and thus is less well
25
characterized. This complex contains a protein called rictor instead of raptor. mTORC2
activates Akt, by phosphorylating it at the Ser-473 residue (164). The identity of the
kinase, which is responsible for the Ser-473 phosphorylation of Akt was largely elusive.
Phosphorylation of Akt at this residue, besides at Thr-308, is absolutely necessary for the
activation of this protein, which gives an indirect measurement of insulin stimulation on
PI3 kinase activation (3). RNA-interference study as well as in vitro kinase assay
confirmed that mTOR and rictor but not raptor phosphorylates full length Akt at Ser-473
and also facilitates phosphorylation at Thr-308 by PDK-1. The mTOR-rictor complex is
therefore suggested as a potential drug target for cancer and diabetes (164). However,
how insulin signaling activates this complex, which in turn mediates the activation of
Akt, has not been demonstrated yet. Both TORC1 and TORC2 in different species form
multimeric complexes via a TOR-TOR interaction (90, 163).
Mammalian TOR complexes, especially mTORC1, integrate various signaling
pathways and establish crosstalk between them. Activation of PI3 kinase pathway
activates mTORC1 (Fig. 1, green lines). Treatment with rapamycin, an inhibitor of
mTORC1, abolishes the insulin-mediated induction of G6PD expression in primary rat
hepatocytes (202), which strongly suggests that the activation of this pathway
downstream to PI3 kinase is required to mediate the insulin induction of G6PD.
However, prolonged activation of this complex inhibits the PI3 kinase pathway by a
feedback mechanism (Fig. 1, pink line). A more detailed discussion in this regard will be
followed.
AMPK
AMPK is a sensor of cellular energy level. Increasing the cellular AMP/ATP ratio
activates this kinase, which in turn, switches off ATP consuming processes, such as, the
anabolic metabolism pathways, and switches on ATP generating processes or the
catabolic pathways (97).
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AMPK is a heterotrimer and composed of a catalytic a subunit and regulatory b
and g subunits. In mammals, each of these subunits is encoded by multiple genes. In
mammalian cells, AMP activates AMPK in three different ways: by allosterically
activating the AMPK complex formation, by promoting phosphorylation at Thr-172 of
the kinase domain of the a subunit and by inhibiting dephosphorylation at Thr-172 by
making AMPK a poor substrate of protein phosphatase 2C (76). The AMP-mediated
activation of AMPK is antagonized by high concentration of ATP.
The upstream kinase that activates AMPK by phosphorylating it at Thr-172 is
only recently identified as LKB1 (74). Like AMPK, LKB1 forms a heterotrimer with two
other proteins, MO25 and STRAD. Formation of the heterotrimer is required for the
catalytic activity of LKB1 as well as for its cytoplasmic localization. Activators of
AMPK do not seem to activate LKB1. Thus, it has been suggested that LKB1 is
constitutively active, and the regulation of AMPK phosphorylation is mediated via
regulation of AMPK but not LKB1. LKB1 activates 11 AMPK-related kinases by
phosphorylating them at Thr residues equivalent to Thr-172 of AMPK. Thus, LKB1 is
suggested to act as a master upstream kinase, which mediates its function by AMPK and
AMPK-related kinases (74, 77). The role of this kinase in cellular AMPK regulation is
still unknown.
Various cellular stresses, which deplete ATP, and increase the AMP/ATP ratio,
like metabolic poisoning and pathological stress will activate AMPK. Metabolic poisons
include inhibitors of tricarboxylic acid cycle (arsenite), respiratory chain (azide),
mitochondrial ATP synthase (oligomycin) and uncouplers of oxidative phosphorylation
(dinitrophenol, DNP), whereas pathological stresses include glucose deprivation,
ischemia, hypoxia, oxidative and hyperosmotic stress. Exercise or contraction also
enhances AMPK activation due to increasing ATP consumption in skeletal muscle (28,
74, 76). Two widely used antidiabetic drugs, metformin (233) and thiazolidinediones
(59), have recently been shown to activate AMPK. While thiazolidinediones appear to
enhance cellular AMP/ATP ratio, the mechanism of action by which metformin activates
AMPK has not been demonstrated.
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AMPK and metabolic gene regulation:
A central role for AMPK in regulating intracellular metabolism is emerging.
Activated AMPK phosphorylates acetyl-CoA carboxylase (ACC) at Ser-79, Ser-1200 and
Ser-1215 (45, 130). AMPK is the only known kinase that phosphorylates at Ser-79 of
ACC (75). Phosphorylation of this serine inhibits ACC activity. ACC converts acetyl
CoA into malonyl CoA and is known as the rate limiting enzyme of the fatty acid
biosynthetic pathway. Malonyl CoA is not only involved in de novo fatty acid
biosynthesis, but also inhibits carnitine: palmitoyl-CoA transferase-1 (CPT1), the rate-
limiting enzyme for fatty acid oxidation in mitochondria. Inhibition of ACC activity by
phosphorylation will inhibit fatty acid biosynthesis and increase fatty acid oxidation.
AMPK also plays a role in regulating metabolic capacity by regulating the expression of
genes for the metabolic enzymes. Activation of AMPK down regulates lipogenic genes
including FAS and ACC (29, 53, 74). Inhibition of lipogenic genes is mediated through
down regulation of the transcription factors required for the lipogenic gene expression.
These transcription factors are the sterol regulatory element binding protein (SREBP) -1c
(233) and the hepatic nuclear factor-4a (HNF4a) (86, 112). Activation of AMPK
enhances glucose uptake by increasing glucose transporter (GLUT4) levels in muscle.
Activated AMPK enhances DNA binding ability of the transcription factor MEF2 in
muscle, which is the possible mechanism of increase in GLUT 4 level upon AMPK
activation (232). A recent report revealed that the activators of AMPK, such as 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR) and DNP enhance GLUT4
translocation and glucose uptake in adipocytes in a p38 MAP kinase-dependent pathway
(223). Activation of AMPK reduces the activity of HMG CoA reductase, the rate limiting
enzyme for cholesterol biosynthesis in liver (36, 65). AMPK activation is also associated
with increased activation of glycolytic enzymes such as 6-phosphofructo kinase, although
the exact mechanism is not known (120). AMPK, thus, plays a major role in the cellular
metabolism regarding glucose and lipid homeostasis. Involvement of AMPK in
regulation of insulin signaling (Fig. 1, orange lines) will be discussed in a later section.
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PUFA
Fatty acids with more than one double bond are called polyunsaturated fatty acids
or PUFAs. Most of the PUFAs belong to the essential fatty acid family, as they cannot be
synthesized de novo and a dietary supplement from plant oil is necessary. There are two
major groups of essential fatty acid families, known as the w-6 and w-3 family. The
precursors of these two families are linoleic acid (18:2) and alpha linolenic acid (18:3),
respectively. The omega carbon is the carbon in the methyl group and since the last
double bond of linoleic and alpha linolenic acids are 6 and 3 carbons away from the
methyl group, they are named as w-6 and w-3 fatty acid, respectively. The first double
bond in these two fatty acids is 9 carbons away from the carboxylic or delta end.
Mammals cannot add double bonds any further away from the carboxylic end than nine
carbons and thus w-6 and w-3 fatty acids cannot be synthesized de novo.
Linoleic acid is converted into g-linolenic acid (GLA, 18:3) by D-6 desaturase,
which is elongated into dihomo-g-linolenic acid (DGLA, 20:3) by the action of elongase.
DGLA is converted into arachidonic acid (20:4) by D-5 desaturase. GLA, DGLA and
arachidonic acid all belong to the w-6 fatty acid family. On the other hand, a-linolenic
acid is converted into eicosapentanoic acid (EPA, 20:5) by sequential desaturation,
elongation and desaturation by D-6 desaturase, elongase, and D-5 desaturase,
respectively. EPA is converted into docosahexaenoic acid (DHA, 22:6) by elongation,
followed by desaturation by D-4 desaturase. Both EPA and DHA belong to the w-3 fatty
acid family. PUFAs are involved in making membrane structures as part of
phospholipids. Activation of phospholipase A2 releases PUFAs (especially arachidonic
acid) from the sn-2 position. In our body PUFAs are found in their cis-conformation in
the lipid bilayer, which enhances membrane fluidity.
Three of the twenty carbon PUFAs, DGLA, arachidonic acid and EPA, can be
metabolized into eicosanoids. The enzyme cyclooxygenase (COX) catalyzes the
production of the prostanoid families of prostaglandins and thromboxanes, whereas, the
enzyme lipooxygenase (LOX) catalyzes the production of leukotrienes. A family of
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cytochrome p450 dependent epoxygenases has been shown to act on arachidonic acid to
produce epoxyeicosatrienoic acids (EET), which have anti-inflammatory action. The
prostanoids are known to act via G protein-coupled receptors. Depending on the G-
protein linkage, prostanoids can activate adenylate cyclase (makes cAMP and activates
PKA), PLC (activates PKC and increases cellular Ca2+ concentration), or the inhibitory G
protein, Gi (inhibits cAMP production or activates PLCb and elevates intracellular Ca2+
level) (10, 44, 133, 173). Arachidonic acid inhibits lipogenic gene expression in 3T3-L1
adipocytes via prostanoids by activating Gi (123). However; this mechanism differs from
the PUFA-mediated inhibition of hepatic lipogenic gene expression (95).
PUFA-mediated regulation of gene expression:
PUFAs are known to inhibit expression of hepatic glycolytic and lipogenic genes
both in vivo and in hepatocytes in culture. Addition of w-6 or w-3 fatty acids, but not
saturated (like palmitate, 16:0, or stearate, 18:0) or monounsaturated fatty acids (like
oleate, 18:1), to a high-carbohydrate diet inhibits lipogenic gene expression (37, 96).
Several transcription factors are regulated by PUFA that in turn, regulate genes involved
in fatty acid metabolism. In this context, regulation of the nuclear receptors such as
PPAR, liver x receptor (LXR), HNF-4a and SREBP, by PUFA have been reported.
PPAR family proteins bind to the promoter region of many genes involved in
fatty acid transport, desaturation and oxidation as a heterodimer with retinoid x receptor
(RXR) (93). Direct binding of eicosapentanoic acid, 20:5, to PPAR makes a stable
conformation, which helps to recruit co-activators to this receptor (219). LXRs (a and b)
bind to oxysterols and directly regulate hepatic cholesterol biosynthesis. LXRs, upon
binding to the oxysterols, at the same time, indirectly up regulate hepatic lipogenic gene
expression by increasing the expression of SREBP1c (157). PUFAs, especially
arachidonic acid and with a lower effect linoleic acid, interferes with the binding of
oxysterols to LXR and thus inhibit LXR-mediated gene regulation (142). HNF4 a
activates genes involved in bile acid synthesis, carbohydrate metabolism and
apolipoprotein synthesis by binding to the promoter region of the corresponding genes as
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homodimers. Fatty acyl-CoAs can directly bind to HNF4 a at its ligand-binding domain
and regulate its activity. While binding of saturated fatty acyl CoAs (14:0-CoA or 16:0
CoA) activate HNF4 a, binding of 18:3-CoA, 20:5 CoA and 22:6-CoA to HNF4 a inhibit
its effect on gene expression (94, 211).
The best-characterized transcription factor involved in PUFA-mediated inhibition
of gene transcription is SREBP-1c. SREBPs are transcription factors involved in
regulation of cholesterol and lipid synthesis. SREBP-1 (1a and 1c) is involved in
regulation of lipogenic genes and triglyceride synthesis, whereas SREBP-2 regulates
cholesterol synthesis. SREBPs are transcribed as precursor proteins (pSREBP), which
upon cellular stimulations such as sterol depletion, are cleaved into the transcriptionally
active (nSREBP) form and travel to the nucleus. Unlike nuclear receptors, SREBPs do
not bind fatty acids directly, however fatty acids regulate the nuclear abundance of
nSREBP. Intracellular cholesterol distribution is affected by PUFAs. Cholesterol is
associated with spingomyelin while bound to plasma membrane. Treatment of cells with
PUFAs stimulates the activity of sphingomyelinase, which redistributes cholesterol from
plasma membrane to the endoplasmic reticulum. This event of cholesterol redistribution
inhibits formation of nSREBP and attenuates transcriptional activation of SREBP
regulated genes (214). PUFA inhibits the accumulation of SREBP-1 but not SREBP-2
mRNA in the liver of intact animals and in primary rat hepatocytes. In this regard, the
most effective PUFAs are the ones with 20 or longer carbon chain, however, the
monounsaturated fatty acid oleate, shows some effect (220). A recent report has
demonstrated that docosahexaenoic acid, inhibits SREBP-1c mRNA as well as nSREBP-
1c abundance in primary rat hepatocytes via the Erk MAP kinase and 26S proteosome-
dependent pathways (19). Thus, PUFA plays a major role in gene expression at the
transcriptional level via various mechanisms.
PUFAs regulate gene expression at posttranscriptional level, as well, at multiple steps. In
the case of G6PD, PUFAs inhibit the gene expression at the pre-mRNA splicing step both in
intact animals and in rat hepatocytes (5, 175, 191), whereas, PUFAs decrease the stability of
GLUT 4 (193) and SCD I (168) mRNAs in the cytoplasm of 3T3 L1 adipocytes. Deficiency of
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w-3 PUFA content in diet inhibits GLUT 1 expression in rat brain without affecting the mRNA
synthesis, which indicates a posttranscriptional regulation of GLUT1 expression by w-3 PUFA
(152). Dietary PUFA-mediated inhibition of transcription of the SREBP-1 gene does not solely
account for the decrease in the abundance of SREBP-1c mRNA by PUFA (221, 222). This
observation suggests that SREBP-1 gene regulation at least in part, is mediated via
posttranscriptional regulation by PUFA. The details of the mechanisms by which PUFAs
regulate these genes at the posttranscriptional steps remain largely unexplored.
Interference of insulin signal transduction pathway by various
signaling molecules:
Insulin signal transduction pathway, as discussed earlier, is activated when insulin
binds to its receptor at the cell surface. The insulin receptor, which is a tyrosine kinase,
upon activation, phosphorylates its own tyrosine residues (Fig. 1). These phospho-
tyrosine residues of insulin receptor are recognized and bound by IRS proteins and in turn
IRS is phosphorylated at its own tyrosine residues by the insulin receptor. Tyrosine-
phosphorylated IRS is then recognized and bound by the adapter subunit of PI3 kinase. A
stable complex formation between the IRS and the PI3 kinase activates the later protein,
which in turn activates the downstream effector protein Akt and various cellular
processes are turned on (169).
The insulin signal transduction pathway can be inhibited by Ser-phosphorylation
of IRS-1. Various Ser residues (Ser-307, -612, -632) of IRS-1 have been identified,
whose phosphorylation inhibits the PI3 kinase pathway and thus insulin signal
transduction (Fig. 1) (62, 143, 160). The exact mechanism by which Ser phosphorylation
of IRS-1 interferes with the PI3 kinase pathway is not clear; however, several plausible
mechanisms have been suggested. Ser-307 is located near the PTB domain of IRS-1,
which binds the phosphorylated insulin receptor. It has been hypothesized that Ser-307
phosphorylation of IRS-1 could cause a conformational change, which in turn could
reduce the affinity of IRS-1 for the insulin receptor and thus terminate the signaling
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pathway (1, 2). On the other hand, Ser 612 and 632 are located near the tyrosine residues
of the PI3 kinase-binding site. Phosphorylation of these Tyr residues is necessary for the
binding to the adapter subunit of PI3 kinase. Ser-phosphorylations at this site might
interfere with the Tyr-phosphorylation and in turn might inhibit the binding to the PI3
kinase (155). Interestingly, prolonged insulin treatment induces Ser-phosphorylation of
various residues of IRS-1, which suggests the existence of a feedback mechanism, which
uncouples IRS-1 from its upstream or downstream binding partners. In the next few
paragraphs I am going to discuss the involvement of various signaling molecules that
interfere with the PI3 kinase pathway and thus modulate insulin signaling. These
signaling molecules are: various MAP kinases, PKCs, mTOR, fatty acids and AMPK.
These pathways either independently or in concert interfere with the insulin signaling.
MAP kinases: Activation of various MAP kinases (Erk, Jnk and p38) increases
Ser phosphorylation of IRS-1 followed by inhibition of Akt phosphorylation and PI3
kinase activity in various cell types (Fig. 1, blue lines) (46, 47, 60, 83, 153). A central
role of JNK MAP kinase in obesity and insulin resistance via activation of Ser-307
phosphorylation and inhibition of tyrosine phosphorylation of IRS-1 has been established
in ob/ob mice (83). TNF-alpha-mediated inhibition of the PI3 kinase pathway involves
the activation of the Erk, JNK and/or p38 MAP kinase pathways (46, 60, 160). Over
expression of the upstream kinases (MKKs) of these pathways also interferes with the
PI3 kinase activation. Enhanced basal level accumulation of p38 MAP kinase has been
reported in adipocytes of type 2 diabetic patients, which correlates with the down
regulation of GLUT4 expression, an indication of insulin resistance in these patients (30).
Thus, activation of various MAP kinases by different stimuli causes impairment of
insulin signaling.
PKCs: Various isoforms of PKCs can inhibit insulin signaling in different cell
types. Activation or over expression of conventional, novel or atypical PKC isoforms
interfere with the PI3 kinase pathway. In this regard, hyperglycemia enhances the
activation of a conventional PKC, PKC b, which is responsible for insulin resistance;
however, the exact mechanism has not been demonstrated (104). Over expression of
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conventional PKC isoforms have been reported to inhibit the kinase activity of the insulin
receptor (18). Activation of novel PKCs (d and q) also inhibit the PI3 kinase pathway by
inducing Ser-307 phosphorylation of IRS-1 or by inhibiting the kinase activity of the
insulin receptor (33, 101, 167). Over expression of PKC z, an atypical PKC, causes Ser
phosphorylation of IRS-1 and inhibits the PI3 kinase pathway in NIH3T3 and Fao cells
(115, 155). To the contrary, various isoforms of PKC, upon activation, can positively
modulate the PI3 kinase pathway. For example, activation of various isoforms of PKC
(b,d and e) has been shown to enhance insulin-stimulated glucose transport in NIH 3T3
cells (34, 42). Insulin enhances PKC d activity in muscle cells and in hepatoma cell lines
(21, 32). The atypical PKCs z and l are activated by PDK-1 and enhance GLUT4
translocation in adipocytes and muscle cells. Over expression of these isoforms enhance
both the basal and the insulin-stimulated glucose transport (12, 51). Thus, it seems that,
depending on cell types, activation of various isoforms of PKC can either stimulate or
inhibit insulin signaling. This provides an example where a complex cross talk between
two signaling pathways exists and creates a balance between activation and/or inhibition
of one of these pathways by the other.
mTOR: mTOR acts as a downstream effector protein of the PI3 kinase pathway.
As described earlier, activated Akt inhibits the GAP activity of TSC1/TSC2 complex and
thus, activates mTOR by recruiting Rheb to its kinase domain (Fig. 1, green lines).
Insulin-mediated induction of lipogenic gene expression depends on activated mTOR. In
this regard, inhibition of mTOR by rapamycin abolishes the insulin-induction of G6PD
mRNA in primary rat hepatocytes (202). However, sustained activation of mTOR, which
occurs in pathological conditions such as obesity induced by dietary intake of 40% or
more fat (Fig. 1, the thick purple line), causes insulin resistance via Ser-phosphorylation
of IRS-1 by mTOR/S6K-1 pathway (Fig. 1, pink line) (197). This suggests that over
activation of mTOR creates an imbalance in insulin signaling and generates a feed back
inhibition of the PI3 kinase pathway.
Fatty acids: High-fat diet or presence of fatty acid in culture medium interferes
with insulin signaling by activating various inhibitory pathways. Activation of mTOR,
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MAP kinases, various isoforms of PKCs, PKA and inhibitor kB kinase (IKK-b) by fatty
acids have been implicated in this regard (Fig. 1). A few examples of activation of each
of these pathways by dietary fat or free fatty acids and an impairment of insulin signaling
are as follows. A diet containing 40% or more fat enhances mTOR pathway in intact
animals, which in turn elevates Ser-307 phosphorylation of IRS-1 and decreases Akt
phosphorylation (197). Various MAP kinases are activated in obese animal models. In
ob/ob mice activation of JNK has been reported leading to insulin resistance (83).
Presence of arachidonic acid in culture media activates p38 MAP kinase pathway in
HeLa cells, HL60 promyelocytic leukemic cells, and human neutrophils (81). Free fatty
acids mediate insulin resistance in 3T3-L1 adipocytes via activating JNK and TNF-alpha
(137). PUFAs increase adenylate cyclase activation, which in turn enhances cAMP and
activates PKA (7, 8, 131, 132). This effect is specific to the brain and probably not of
consequence in liver. However, a recent report shows that p38 MAP kinase is a
downstream effector of PKA (27), which can lead to attenuation of insulin signal
transduction. Free fatty acids can also induce activation of PKC d and q leading to insulin
resistance both in muscle and liver (110, 229). Inhibitor kB kinase (IKK-b) could also be
involved in free fatty acids-mediated insulin resistance. IKK-b is activated by PKC q (62)
and p38 MAP kinase (46), both of which could be activated by free fatty acids. As IRS-1
is a direct in vitro substrate of IKK-b, it is likely that IKK-b can phosphorylate IRS-1 and
regulate insulin sensitivity (62). Dietary or free fatty acids have also been implicated in
attenuation of insulin signaling where the involvement of the inhibitory pathways has not
been shown. For example, diet containing w-3 and w-6 fatty acids reduce the number of
insulin receptors, decrease the tyrosine phosphorylation of insulin receptor and IRS-1 and
decrease the PI3 kinase activity in liver (192). The 22:6 PUFA, docosahexaenoic acid,
has recently been reported to inhibit insulin-mediated induction of Akt phosphorylation
in primary rat hepatocytes (19). The exact regulatory mechanisms involved in attenuation
of insulin signaling by PUFA in these cases have not been reported yet.
AMPK: PUFAs present in diet or culture medium activate AMPK (Fig. 1, cyan
line), both in the liver of intact animals and in primary hepatocytes. Activation of AMPK
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can both positively and negatively regulate insulin signaling. The positive mechanisms
are as follows: 1) Activation of AMPK leads to down regulation of lipogenic genes in
liver and inhibits lipolysis and thus, inhibits production of free fatty acids (29, 53, 185).
As discussed earlier, an increase in the cellular free fatty acid content impairs insulin
signaling by various mechanisms, prolonged inhibition of which results in induction of
insulin sensitivity. 2) Activation of AMPK leads to down regulation of the mTOR/S6K-1
pathway (Fig. 1, solid orange line) (78). Prolonged activation of mTOR, which takes
place under pathological condition, attenuates insulin signaling (Fig. 1, pink line). Thus,
inhibition of this pathway by AMPK under such conditions enhances insulin sensitivity.
The inhibitory mechanisms by which AMPK attenuates insulin signaling are as follows:
1) Activation of PI3 kinase activates mTOR/S6K-1 (Fig. 1, green lines), which is located
downstream of Akt. Inhibition of mTOR/S6K-1 under non-pathological condition by
activated AMPK thus, attenuates insulin signaling. 2) AMPK activation can lead to the
activation of p38 MAP kinase (113, 114, 204), a known inhibitor of the PI3 kinase, and
thus, AMPK can indirectly inhibit insulin-signaling (Fig. 1, broken orange line).
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Summary and hypothesis:
The summary of this section is shown in figure 1. Insulin upon binding to its
receptor activates the insulin-signaling pathway by recruiting IRS proteins to the
receptor. IRS becomes tyrosine-phosphorylated by the insulin receptor and in turn
recruits PI3 kinase and activates it. PI3 kinase in turn activates the downstream effector
protein Akt by facilitating its phosphorylation at Thr-308 and Ser-473. Activation of Akt
enhances the mTOR pathway by inhibiting the GTPase activity of TSC1/TSC2, which in
turn facilitates binding of small GTP-binding protein Rheb to mTOR. Activation of
mTOR phosphorylates and activates S6K-1. Activation of this signaling cascade turns on
various cellular responses, which eventually stimulates cell growth, glycolytic and
lipogenic gene expression, protein translation etc.
A primary mechanism of inhibition of insulin signaling is by Ser-phosphorylation
of IRS proteins. Ser-phosphorylation of IRS either interferes with its binding to the
insulin receptor or to the PI3 kinase which causes a down regulation of insulin signaling
pathway. Activation of various MAP kinases, PKC, TNF-alpha and mTOR either alone
or in combination can cause Ser-phosphorylation of IRS proteins. Ser-phosphorylation of
IRS by mTOR suggests a feedback loop of insulin signaling. Activation of AMPK
inhibits mTOR activation, which can have both positive and negative impact on insulin
signaling.
High-fat diets, free fatty acids and/or various PUFAs activate MAP kinase
pathways, either directly or via activating PKC and/or TNF-alpha (Fig. 1, brown lines).
High-fat diet can also activate mTOR, which generates a pathological condition (Fig. 1,
the thick purple line). Activation of these pathways results in Ser-phosphorylation of
IRS-1 (Fig. 1, blue and pink lines). PUFAs also activate AMPK (Fig. 1, cyan line), which
interferes with the PI3 kinase/mTOR pathway (Fig. 1, orange lines) and at the same time
inhibits lipogenic gene expression. Starvation, which causes inhibition of lipogenic gene
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expression, also activates MAP kinase (via activating PKA) and AMPK (Fig. 1, shaded
yellow lines) and thus can have negative impact on insulin signaling.
G6PD is a lipogenic enzyme, which is induced by insulin both in intact animals
and in primary hepatocytes. Insulin-mediated induction of G6PD in primary rat
hepatocytes follows the PI3 kinase pathway. Induction of this gene expression by insulin
is attenuated upon starvation or high-fat diet in intact animals or by PUFA in culture
medium. PUFAs do not inhibit the basal level expression of G6PD, suggesting that it
only attenuates the insulin-mediated induction of this gene. From this background and
information from the literature, I hypothesized that arachidonic acid, a PUFA, when
present in the medium along with insulin, interferes with the PI3 kinase pathway, and
thus, attenuates the effect of insulin on G6PD gene expression. Prolonged inhibition of
this pathway can cause insulin resistance but in a non-pathological condition will
decrease the expression of the lipogenic genes. We further hypothesized that arachidonic
acid causes activation of inhibitory pathways, such as, MAP kinases, PKC and/or mTOR,
which can interfere with the insulin signaling probably by increasing Ser-phosphorylation
of IRS-1. We also hypothesized that arachidonic acid activates the AMPK pathway,
which attenuates G6PD gene expression, either directly, or via activating other inhibitory
pathways, which interfere with insulin signaling.
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Figure 1.   Integration of various signaling pathways in metabolic gene regulation. The
color code of the figure is as follows: Green lines, activation of mTORC1 as a down
stream target of PI3 kinase. Thick purple line: over activation of mTORC1 by high fat
diet. Pink line: Ser-phosphorylation of IRS via activation of S6K-1. Brown lines:
activation of MAP kinase, as a direct or indirect effect of PUFA. Red lines: activation of
MAP kinase by PKC and Ser-phosphorylation of IRS by PKC.  Thin cyan line: activation
of AMPK by PUFA. Shaded yellow lines, activation of MAP kinase and AMPK due to
starvation. Broken orange line: activation of MAP kinase by AMPK. Solid orange line:
down regulation mTORC1 by AMPK. Blue lines, Ser-phosphorylation of IRS by MAP
kinases and inhibition of PI3 kinase pathway. Short black arrows, involvement of PI3
kinase, Akt and mTOR in regulation of various processes. Long black arrow:
involvement of mTORC2 in phosphorylation of Akt at Ser-473.
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Polyunsaturated fatty acids are potent inhibitors of lipogenic gene expression in liver.
The lipogenic enzyme, glucose-6-phosphate dehydrogenase (G6PD) is unique in this gene
family in that fatty acids inhibit at a posttranscriptional step.  In this study, we provide
evidence for a signaling pathway for the arachidonic acid inhibition of G6PD mRNA
abundance.  Arachidonic acid decreases the insulin induction of G6PD expression; by itself,
arachidonic acid does not inhibit basal G6PD mRNA accumulation.  The insulin-
stimulation of G6PD involves the phosphoinositide-3-kinase (PI3-kinase) pathway (Wagle
A., Jivraj, S., Garlock, G.L., and Stapleton, S.R. (1998) J. Biol. Chem. 273, 14968-14974).
Incubation of hepatocytes with arachidonic acid blocks the activation of PI3-kinase by
insulin as observed by a decrease in Ser473 phosphorylation of Akt, the downstream effector
of PI3-kinase.  The decrease in PI3-kinase activity was associated with an increase in Ser307
phosphorylation of IRS-1.  Western analysis demonstrated increased phosphorylation of
p38 MAPK in arachidonic acid treated cells, while ERK and JNK activity was not changed.
Incubating the hepatocytes with the p38 MAPK inhibitor, SB203580, blocked the
arachidonic acid inhibition of G6PD mRNA accumulation.  Furthermore, SB203580
decreased the arachidonic acid-mediated Ser307 phosphorylation of IRS-1 and rescued Akt
activation that was otherwise decreased by arachidonic acid.  Thus, arachidonic acid
inhibits the insulin stimulation of G6PD mRNA accumulation by stimulating the p38
MAPK pathway thereby inhibiting insulin signal transduction.
Insulin is the central hormone required for the activation of lipogenic genes in the liver.
Feeding animals a high carbohydrate diet enhances the expression of the lipogenic genes.  This
effect involves the stimulatory actions of both dietary glucose and insulin (1,2).  In contrast,
dietary polyunsaturated fats attenuate the stimulatory effect of feeding a high carbohydrate diet
(3,4).  We have used glucose-6-phosphate dehydrogenase (G6PD)1, a member of the lipogenic
gene family as a model system for studying the mechanism of action of fatty acids.  The
advantage of this model is that insulin is the primary inducer of G6PD expression and fatty acids
such as arachidonic acid are the primary inhibitors of G6PD expression; this regulation is
independent of other hormonal requirements (5,6).  The intracellular mechanisms by which
polyunsaturated fats inhibit G6PD or other lipogenic genes are not completely understood.
Inhibition by polyunsaturated fatty acid may represent a direct action of fatty acids on factors
involved in gene expression.  Alternatively, fatty acids may act indirectly via the inhibition of
stimulatory signal transduction pathways of glucose or insulin.  We hypothesized that fatty acids
inhibit G6PD expression by inhibition of the insulin induction.
Insulin transduces its signal upon binding to the insulin receptor.  Transduction of this signal
in liver involves phosphorylation of two intracellular substrates, insulin receptor substrate (IRS)-1
and IRS-2 (7).  These proteins play complementary roles in insulin signaling (8).  Activation of
PI3-kinase is associated with the stimulatory effects of insulin on metabolic pathways including
lipogenesis (9-11).
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The IRS proteins can be phosphorylated on both tyrosines and serines.  A known mechanism
for the inhibition of IRS-1 activation is by phosphorylation at serines 307, 612 and 632 (12).
These serine residues, when phosphorylated might interfere with the interaction between IRS-1
and the insulin receptor or PI3-kinase (13,14).  Among the factors known to cause serine
phosphorylation of IRS-1 are the mitogen-activated protein kinases (MAP kinases).  Activation of
the MAP kinases, extracellular regulated kinase (Erk) (15,16), c-Jun amino-terminal kinase (JNK)
(17-19), or p38 MAP kinase (p38 MAPK) (17,20) is associated with the development of insulin
resistance in muscle and adipose tissue.
Known activators of MAP kinases include tumor necrosis factor a (TNFa) and very high fat
diets.  TNFa, a potent mediator of insulin resistance, activates all three of the MAP kinases.
Phosphorylation and activation of p38 MAPK by TNFa  correlates with IRS-1 serine
phosphorylation and a decrease in PI3-kinase activity (17,20).  In muscle and adipose tissue, this
results in the decrease in glucose uptake associated with insulin resistance.  Likewise, diets
containing 40% or more of the energy content as fat, also decrease PI3-kinase activation and
result in an insulin resistant phenotype in intact animals (21-23).  This may involve activation of
MAP kinases (18,19).  In contrast to the pathological effects of large amounts of dietary fat,
addition of smaller amounts of polyunsaturated fat (less than 20% of energy) to a high
carbohydrate diet has a potent but reversible inhibitory effect on lipogenic gene expression (3).
The question remains if modulation of insulin signaling by low levels of dietary fat is involved in
the non-pathological regulation of metabolic pathways and in particular the de novo synthesis of
fatty acids.
In this paper, we report a signaling pathway by which polyunsaturated fatty acids inhibit
G6PD expression.  We demonstrate that arachidonic acid inhibits the insulin-mediated induction
of G6PD mRNA abundance in primary rat hepatocytes.  This inhibition of insulin action occurs
by Ser307 phosphorylation of IRS-1.  Incubation of hepatocytes with arachidonic acid results in an
activation of p38 MAPK, thereby inducing IRS-1 serine phosphorylation, and reducing PI3-
kinase activation.  Inhibition of p38 MAPK results in a loss of the arachidonic acid-mediated
inhibition of G6PD expression.  This is the first report of p38 MAPK involvement in the
regulation of a lipogenic gene by polyunsaturated fatty acids.
EXPERIMENTAL PROCEDURES
Animal Care and Cell Culture - Male Sprague-Dawley rats (175-225g) were starved 16 h prior
to surgery.  Hepatocytes were isolated by a modification of the technique of Seglen (24) as
previously described (6).  Hepatocytes (3.1 X 106) were placed in 60-mm dishes coated with rat-
tail collagen and incubated in Hi/Wo/Ba medium (Waymouth MB752/1 plus 20 mM HEPES, pH
7.4, 0.5 mM serine, 0.5 mM alanine, 0.2% bovine serum albumin).  Medium containing the
treatments indicated in the figure legends was added after 24 h in culture.  Fatty acids (Nu-Check
Prep) were added as a complex bound to bovine serum albumin (25).  The fatty acid (4 mM),
albumin (1 mM) stocks contained butylated hydroxytoluene (0.1%), and the medium contained
a-tocopherol phosphate, disodium (10 µg/liter), to minimize oxidation of fatty acids.  The
concentration of arachidonic acid used (175 µM) results in the maximum inhibition of G6PD
expression (6,26).  Hepatocytes not receiving arachidonic acid are treated with an equivalent
amount of albumin and butylated hydroxytoluene.  Because arachidonic acid is metabolized
rapidly by the hepatocytes, the medium was replenished every 12 h.  The Erk inhibitor
(PD98059) was purchased from Cell Signaling Technology; the inhibitors of PI3kinase
(LY294002), and p38 MAPK (SB203580) were purchased from Calbiochem.
Isolation of Total RNA and Ribonuclease Protection Assay - Total RNA from 2-3 plates per
treatment was isolated by the method of Chomczynski and Sacchi (27).  Quantitation of RNA was
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performed using RNase protection assays (Ambion, Inc.).  Rat G6PD exon 13!template was
synthesized as described previously (26).  The templates for the rat b-actin and 18s probes were
purchased from Ambion, Inc.  Probe synthesis, hybridizations and RNase digestion were as
previously described (28).  The resulting hybridization products protected from RNase digestion
were separated in a 5% denaturing polyacrylamide gel.  Images were visualized by storage
phosphor technology and quantified using ImageQuaNT software by Molecular Dynamics
(Amersham Biosciences).
Preparation of Cell Extract and Western Blot Analysis - The hepatocytes were lysed in buffer
containing 10mM Tris, pH 7.4, 1% SDS and total protein was quantified using a BCA protein
assay (Pierce).  Equal amounts of denatured protein (40 mg per lane) were loaded onto a 7.5%
polyacrylamide gel and transferred to Immun-Blot‘ PVDF membrane (Bio-Rad) at 100V for
1.5h.  The membranes were blocked in 5% nonfat dry milk for 1h and incubated with primary
antibody diluted in 5% bovine serum albumin overnight at 4°C.  The primary antibodies against
phosphorylated Akt (Ser473), phosphorylated IRS-1 (Ser307 and Ser612), phosphorylated p38 MAPK
(Thr180/Tyr182), phosphorylated Erk (Tyr183/185), phosphorylated JNK (Thr183/Tyr185) and total Akt,
IRS-1, p38 MAPK, Erk, and JNK were obtained from Cell Signaling Technology.  Anti rabbit
IgG conjugated with horseradish peroxidase (Cell Signaling Technology) was used as the
secondary antibody, and the immunocomplexes were detected by enhanced chemiluminescence
(Pierce).  Images were visualized with film (Pierce) and quantified by densitometry using
ImageQuaNT software (Molecular Dynamics).
PI3-kinase assay – Rat hepatocytes were harvested with lysis buffer containing 50mM NaCl,
100mM Tris, pH 8, 1% Triton X-100, 5mM EDTA, 10mM NaF, 0.5M NaVO4, 1M DTT, and
protease inhibitors.  Equal amounts of protein (500 mg) from each treatment group were
immunoprecipitated with anti p85 antibody (Upstate) and protein A sepharose beads.  The bead
pellets were washed twice with lysis buffer, once each with TNE buffer (200mM Tris, pH 7.5,
100mM NaCl, 1mM EDTA) and 20mM HEPES, pH 7.5 and suspended in assay buffer (20mM
HEPES, pH 7.5, 10mM MgCl2, 0.2 mg/ml phosphoinositol, 60 mM ATP, 20 mCi [g-32P] ATP).
After 15 minutes in assay buffer, the reaction was terminated by addition of 1M HCl, and the
lipids were extracted with chloroform:methanol (1:1).  The organic phase was loaded on silica gel
TLC plates (10).  The lipids were visualized using autoradiography.
RESULTS
Insulin induces the expression of G6PD mRNA, whereas arachidonic acid attenuates this
effect - Primary rat hepatocytes were used for these studies because they are the only cell culture
system that mimics the effects of dietary polyunsaturated fat on the regulation hepatic G6PD
expression.  In hepatocytes, insulin increases G6PD mRNA abundance and arachidonic acid
inhibits G6PD mRNA amount, similar to the changes in G6PD expression observed in intact
liver, in animals fed a high carbohydrate diet and a diet supplemented with polyunsaturated fat
(6% safflower oil), respectively (6,29).  Furthermore, regulation of G6PD expression occurs at a
nuclear posttranscriptional step in both intact liver and primary hepatocyte cultures (6,28,29).  We
first asked if arachidonic acid per se regulated G6PD expression.  Because G6PD activity is
essential for cell viability, the amount of G6PD mRNA remains readily detectable in the absence
of insulin (Fig. 1).  The addition of arachidonic acid alone did not decrease the expression of
G6PD mRNA.  In contrast, insulin induced G6PD mRNA expression 7-fold, and arachidonic acid
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inhibited this induction by 50% or more. Thus, arachidonic acid appears to inhibit the insulin-
mediated induction of G6PD expression.
Arachidonic acid inhibits Akt-phosphorylation and induces Ser307-phosphorylation of IRS-1 -
Because the arachidonate inhibition is only observed in cells with intact insulin action, we
hypothesized that arachidonic acid interferes with the PI3-kinase pathway and thus prevents the
induction of G6PD mRNA by insulin.  The induction of G6PD mRNA by insulin has been
demonstrated to require the PI3-kinase signal transduction pathway (ref. 30 and data not shown).
The form or metabolite of arachidonic acid that inhibits gene expression is not known.  Thus, the
hepatocytes were preincubated with arachidonic acid to allow time for incorporation of this fatty
acid into membrane phospholipid and/or generation of the relevant intracellular metabolite.  The
rapid signal transduction by the insulin receptor could otherwise have preceded the generation of
the relevant inhibitory form of arachidonic acid.  Insulin induced Akt-phosphorylation 24 to 75-
fold across time points (Figs. 2A and 2B).  This induction was rapid and persisted through 60
minutes.  Pre-incubation of hepatocytes with arachidonic acid attenuated the insulin-mediated
induction of Akt phosphorylation by 50 to 72% across the time points (Figs. 2A and 2B).  The
amount of total Akt was not affected by these treatments (Fig. 2A).  Similarly, arachidonic acid
inhibited PI3-kinase activity by 50% consistent with it being an upstream activator of Akt (data
not shown).
The decrease in Akt phosphorylation in cells incubated with arachidonic acid suggests that
arachidonic acid is inhibiting a step at or prior to PI-3 kinase activation.  Since phosphorylation of
IRS-1 at serines can interfere with its interaction with either the insulin receptor or PI-3 kinase
and thereby inhibits insulin signal transduction (12), we measured changes in the amount of IRS-
1 phosphorylation on 2 different serine residues.  Incubation of hepatocytes with arachidonic acid
prior to and during insulin addition increased IRS-1 Ser307 phosphorylation 4- to 6-fold at each
time point (Figs. 2A and 2C).  Insulin alone caused a smaller but reproducible increase Ser307
phosphorylation.  Arachidonic acid does not cause an increase in the phosphorylation of all
regulatory serines in IRS-1.  In this regard, arachidonic acid did not stimulate an increase in
phosphorylation at Ser612 of IRS-1 (Fig. 2A). While phosphorylation of Ser612 can also abolish
tyrosine phosphorylation of IRS-1 (7), arachidonic acid inhibition of insulin signaling in
hepatocytes does not appear to involve this serine residue.  These results suggest that arachidonic
acid increases Ser307 phosphorylation of IRS-1; this in turn interferes with the PI3-kinase activity
and Akt phosphorylation, which are required for the insulin induction of G6PD mRNA.
Arachidonic acid induces p38 MAPK phosphorylation - To explore the mechanism for the
increase in IRS-1 Ser307 phosphorylation, we determined if arachidonic acid in the presence of
insulin activates serine/threonine kinases involved in serine phosphorylation of IRS-1.  Members
of the MAP kinases family are known to stimulate serine phosphorylation of IRS-1 (15-20).  The
amounts of phosphorylated and activated, as well as, the total amounts of the three MAP kinases,
Erk, JNK and p38 were measured by western blot analyses (Figs. 3A and 3B).  Insulin stimulated
a small but consistent increase in p38 MAPK phosphorylation.  A similar increase was detected
with arachidonic acid, alone (Fig. 3C).  The greatest increase in the phosphorylation of p38
MAPK (4- to 6-fold) was observed with arachidonic acid in the presence of insulin as compared
to no additions.  Furthermore, the increase in p38 MAPK phosphorylation occurred within the
same time frame as the changes in Akt and IRS-1 Ser307 phosphorylation.  The total amount p38
MAPK was not regulated by these treatments (Fig. 3C).  In contrast, arachidonic acid did not
increase the amounts of activated Erk and JNK.  Fluctuations in Erk and JNK activation were
observed across treatments and likely reflect stimulation due to the manipulation of the cells for
the addition of the treatments.  There was no consistent effect of the treatments per se on Erk or
JNK activation.  This result suggests that arachidonic acid stimulates Ser307 phosphorylation of
IRS-1 by activation of p38 MAPK
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Inhibition of the p38 MAPK pathway decreases the arachidonic acid-mediated inhibition of
G6PD mRNA expression - We next tested if the activation of p38 MAPK by arachidonic acid is
responsible for the inhibition of G6PD mRNA accumulation.  The p38 MAP kinase pathway was
inhibited by SB203580.  SB203580 had little or no effect on the insulin-mediated induction of
G6PD mRNA abundance; but abrogated the inhibition by arachidonic acid (Fig. 4).  In contrast,
inhibition of Erk signaling with the inhibitor, PD98059, had no detectable effect on G6PD
regulation by insulin or arachidonic acid (data not shown); consistent with the lack of Erk
activation by arachidonic acid.  To verify that activation of p38 MAPK was involved in the Ser307
phosphorylation of IRS-1, the effects of arachidonic acid on Ser307 phosphorylation of IRS-1 and
Akt phosphorylation were measured in hepatocytes incubated with SB203580.  Arachidonic acid
in the presence of the p38 MAPK inhibitor did not increase the Ser307 phosphorylation of IRS-1
as compared to insulin and SB203580 treated hepatocytes (Fig. 5, compare lanes 4&5 vs. 2&3 for
P-IRS1).  At the same time, Akt phosphorylation in hepatocytes incubated with arachidonic acid
and SB203580 did not decrease with respect to hepatocytes incubated with insulin and SB203580
(Fig. 5, lanes 4&5 vs. 2&3 for P-Akt).  These results are consistent with the idea that activation of
p38 MAP kinase by arachidonic acid impairs the activation of the PI3-kinase by inducing Ser307
phosphorylation of IRS-1, which in turn inhibits the induction of G6PD mRNA by insulin.
Multiple unsaturated fatty acids inhibit insulin signal transduction.  Polyunsaturated fatty
acids of both the w 6 and w3 families inhibit G6PD expression (6).  We asked if other
polyunsaturated fatty acids also inhibit insulin signal transduction.  Eicosapentaenoic acid
(20:5w3) was as effective as arachidonic acid (20:4w6) at both decreasing Akt phosphorylation
and increasing p38 MAPK phosphorylation (Table 1).  The eighteen carbon precursors of these
fatty acids, especially linoleate (18:2) caused similar changes in Akt and p38 MAPK
phosphorylation but were somewhat less effective similar to the lower inhibitory effect of these
fatty acids on G6PD mRNA accumulation both historically (6) and in this experiment (data not
shown).
TNFa induces p38 MAP kinase, inhibits activation of Akt and also diminishes induction of
G6PD by insulin - To corroborate that arachidonic acid activation of p38 MAPK was involved in
its inhibition of G6PD expression, we tested the effect of another activator of p38 MAPK.  TNFa
inhibits insulin-mediated Akt phosphorylation in 3T3-L1 adipocytes myotubes (17,20).  In
addition, TNFa activates p38 and other MAP kinases in various cell-lines, resulting in inhibition
of the PI3-kinase pathway (20).  Incubation of rat hepatocytes with insulin and TNFa resulted in
a concomitant 5-fold increase in phosphorylated p38 MAPK and a 53 to 76% decrease in
phosphorylated Akt across time points (Figs. 6A and 6B, respectively).  These changes in p38
MAPK and Akt phosphorylation occurred within the same time frame as the changes caused by
arachidonic acid.  In addition, TNFa also decreased the insulin induction of G6PD mRNA by
50% (Fig. 6C).  Thus, activation of MAP kinases by multiple effectors is associated with a
decrease in Akt activation and a decrease in the accumulation of G6PD mRNA.
DISCUSSION
In previous work, we have defined a unique posttranscriptional mechanism whereby
polyunsaturated fatty acids inhibit G6PD expression - a decrease in pre-mRNA splicing (26,31).
In the present study, we sought to determine the signaling pathway involved in this inhibition.
We demonstrate that the polyunsaturated fatty acid inhibition of G6PD expression involves
inhibition of the insulin-mediated induction of G6PD (Fig. 1).  This inhibition is a consequence of
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arachidonic acid inhibition of insulin signal transduction via PI3-kinase (Fig. 2).  Incubation of
hepatocytes with insulin and arachidonic acid activated p38 MAPK resulting in Ser307
phosphorylation of IRS-1 (Figs. 2 and 3), a modification which inhibits insulin activation of PI3-
kinase (7).  In confirmation of this, inhibition of p38 MAPK activity, blocks the arachidonic acid
inhibition of G6PD expression, decreases Ser307 phosphorylation of IRS-1, and increases PI3-
kinase activity as measured by Akt phosphorylation (Figs. 4 and 5).  This is the first report of
inhibition of a lipogenic gene in liver via activation of the p38 MAPK pathway.
Polyunsaturated fatty acids have been demonstrated to activate MAP kinases in various cell
types (c.f., (32-34).  In primary rat hepatocytes, the action of arachidonic acid is specific for p38
MAPK; ERK and Jun kinases are not activated by arachidonic acid (Fig. 3).  Activation of p38
MAPK is generally thought to be part of the stress activated signal transduction pathway (35,36)
and in this regard, arachidonic acid is a known generator of toxic peroxides (37,38).  Several lines
of evidence suggest that oxidative stress is not the mechanism by which arachidonic acid in
primary rat hepatocytes is activating p38 MAPK.  First, the extent of p38 MAPK activation is the
same with either arachidonic acid or insulin alone (Fig. 3C).  In addition, arachidonic acid in the
absence of insulin does not inhibit G6PD expression despite readily detectable levels of G6PD
mRNA (Fig. 1).  Second, oxidation of arachidonic acid in the culture system is minimized by
preparation of fatty acid stocks with butylated hydroxytoluene, and the culture medium is
supplemented with additional a-tocopherol.  While these will not completely eliminate oxidation,
peroxidation is not detectable using a thiobarbituric acid assay (6).  More importantly, enhanced
oxidation induces G6PD expression (39,40).  Thus, if arachidonic acid is causing oxidative stress,
an increase in G6PD expression would have been observed.
The mechanism by which arachidonic acid activates p38 MAPK is not clear.  Multiple steps
exist upstream of p38 MAPK and regulate its phosphorylation.  Stress and cytokines generally
induce p38 MAPK via Tak1 or Ask1 (41,42).  Still other reports suggest that protein kinase C is
an important upstream kinase.  Preliminary studies using the inhibitor of protein kinase C,
GF109203X, demonstrated that inhibition of protein kinase C does not block the inhibition of
G6PD expression by arachidonic acid.2  Alternatively, polyunsaturated fatty acids can also
activate AMP activated protein kinase in rat liver and hepatocytes (43,44).  Activation of AMPK
is associated with an increase in p38 MAPK phosphorylation in skeletal and cardiac muscles and
this increase is associated with an increase in glucose uptake (45,46).  While p38 MAPK has not
been shown to be a substrate for AMPK, these results are consistent with AMPK being upstream
in the p38 MAPK signaling pathway.
The mechanism whereby arachidonic acid inhibits insulin signaling in hepatocytes shares
some of the characteristics of the mechanism of insulin resistance caused by consumption of a
high fat diet.  Diets with fat contents of 40% or more inhibit the activation of PI3-kinase by
increasing Ser307 phosphorylation of IRS-1 (23).  Activation of mTOR followed by subsequent
activation of S6 kinase 1 (S6K1) was implicated in this response (47,48) and genetic ablation of
the S6K1 gene protects against insulin resistance in the intact mouse (23).  In primary
hepatocytes, arachidonic acid did not activate S6 kinase and treatment with rapamycin for 1 to 24
h did not ablate the fatty acid inhibition.2  Still others have implicated protein kinase C q in the
Ser307 phosphorylation of IRS-1 and as a mechanism for fat-induced insulin resistance in skeletal
muscle (49).  While our preliminary data is inconsistent with protein kinase C activation, this may
reflect a distinct difference between isolated cells and intact tissue.  Alternatively, it may reflect
distinctly different signal transduction pathways between muscle and liver.
Polyunsaturated fat inhibition of lipogenic gene expression occurs with very low levels of
dietary fat (6% by weight and 14% by kcal; (29).  Such low levels of dietary fat are not associated
with insulin resistance.  The signal transduction mechanism, which we describe, may reflect a
reversible response to changing nutrient conditions.  In this regard, we did not observe a decrease
in total IRS-1 amount (Fig. 2A), even at longer time points, which has been observed during
insulin resistance (16,17).  Regulation of hepatic metabolism by polyunsaturated fats must
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therefore occur at two levels:  first, a reversible regulatory response and second, under prolonged
and excessive stimulus, a down regulation of the insulin signal transduction pathway.
What remains to be established is how these signals are translocated to the nucleus and to the
site of gene expression.  In the case of G6PD, the signals must activate proteins involved in pre-
mRNA splicing.  Cellular signaling events regulate both positive and negative effectors of
splicing. The PI3-kinase and MAP kinase pathways have been implicated in regulation of
alternative splicing (50-53).  Insulin activates alternative splicing of the protein kinase C bII
mRNA via increased phosphorylation of the splicing activator, SRp40 (51,52).  Involvement of
p38 MAPK signaling in shuttling of hnRNP A1, a suppressor of alternative splicing has also been
reported (54).  The mechanisms involved in regulating G6PD pre-mRNA splicing are currently
under investigation.
REFERENCES
1. Hillgartner, F. B., Salati, L. M., and Goodridge, A. G. (1995) Physiol. Rev. 75, 47-76
2. Towle, H. C. (2001) Proc. Natl. Acad. Sci. U S A 98, 13476-13478
3. Clarke, S. D. (2004) Curr. Opin. Lipidol. 15, 13-18
4. Jump, D. B. (2004) Crit. Rev. Clin. Lab. Sci. 41, 41-78
5. Salati, L. M., Adkins-Finke, B., and Clarke, S. D. (1988) Lipids 23, 36-41
6. Stabile, L. P., Klautky, S. A., Minor, S. M., and Salati, L. M. (1998) J. Lipid Res. 39,
1951-1963
7. Shepherd, P. R., Withers, D. J., and Siddle, K. (1998) Biochem. J. 333 ( Pt 3), 471-490
8. Saltiel, A. R., and Kahn, C. R. (2001) Nature 414, 799-806
9. Nadeau, K. J., Leitner, J. W., Gurerich, I., and Draznin, B. (2004) J. Biol. Chem. 279,
34380-34387
10. Ruderman, N. B., Kapeller, R., White, M. F., and Cantley, L. C. (1990) Proc. Natl. Acad.
Sci. U S A 87, 1411-1415
11. Wang, D., and Sul, H. S. (1998) J. Biol. Chem. 273, 25420-25426
12. Le Marchand-Brustel, Y., Gual, P., Gremeaux, T., Gonzalez, T., Barres, R., and Tanti, J.
F. (2003) Biochem. Soc. Trans. 31, 1152-1156
13. Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., and White, M. F.
(2002) J. Biol. Chem. 277, 1531-1537
14. Mothe, I., and Van Obberghen, E. (1996) J. Biol. Chem. 271, 11222-11227
15. De Fea, K., and Roth, R. A. (1997) J. Biol. Chem. 272, 31400-31406
16. Pirola, L., Bonnafous, S., Johnston, A. M., Chaussade, C., Portis, F., and Van Obberghen,
E. (2003) J. Biol. Chem. 278, 15641-15651
17. Fujishiro, M., Gotoh, Y., Katagiri, H., Sakoda, H., Ogihara, T., Anai, M., Onishi, Y.,
Ono, H., Abe, M., Shojima, N., Fukushima, Y., Kikuchi, M., Oka, Y., and Asano, T.
(2003) Mol. Endocrinol. 17, 487-497
18. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K., Karin, M.,
and Hotamisligil, G. S. (2002) Nature 420, 333-336
19. Prada, P. O., Zecchin, H. G., Gasparetti, A. L., Torsoni, M. A., Ueno, M., Hirata, A. E.,
Corezola do Amaral, M. E., Hoer, N. F., Boschero, A. C., and Saad, M. J. (2005)
Endocrinology 146, 1576-1587
20. de Alvaro, C., Teruel, T., Hernandez, R., and Lorenzo, M. (2004) J. Biol. Chem. 279,
17070-17078
21. Taouis, M., Dagou, C., Ster, C., Durand, G., Pinault, M., and Delarue, J. (2002) Am. J.
Physiol. Endocrinol. Metab. 282, E664-671
65
22. Zierath, J. R., Houseknecht, K. L., Gnudi, L., and Kahn, B. B. (1997) Diabetes 46, 215-
223
23. Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S.,
Allegrini, P. R., Kozma, S. C., Auwerx, J., and Thomas, G. (2004) Nature 431, 200-205
24. Seglen, P. O. (1973) Exp. Cell Res. 82, 391-398
25. Mooney, R. A., and Lane, M. D. (1981) J. Biol. Chem. 256, 11724-11733
26. Tao, H., Szeszel-Fedorowicz, W., Amir-Ahmady, B., Gibson, M. A., Stabile, L. P., and
Salati, L. M. (2002) J. Biol. Chem. 277, 31270-31278
27. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159
28. Hodge, D. L., and Salati, L. M. (1997) Arch. Biochem. Biophys. 348, 303-312
29. Stabile, L. P., Hodge, D. L., Klautky, S. A., and Salati, L. M. (1996) Arch. Biochem.
Biophy.s 332, 269-279
30. Wagle, A., Jivraj, S., Garlock, G. L., and Stapleton, S. R. (1998) J. Biol. Chem. 273,
14968-14974
31. Amir-Ahmady, B., and Salati, L. M. (2001) J. Biol. Chem. 276, 10514-10523
32. Hii, C. S., Ferrante, A., Edwards, Y. S., Huang, Z. H., Hartfield, P. J., Rathjen, D. A.,
Poulos, A., and Murray, A. W. (1995) J. Biol. Chem. 270, 4201-4204
33. Hii, C. S., Huang, Z. H., Bilney, A., Costabile, M., Murray, A. W., Rathjen, D. A., Der,
C. J., and Ferrante, A. (1998) J. Biol. Chem. 273, 19277-19282
34. Rao, G. N., Baas, A. S., Glasgow, W. C., Eling, T. E., Runge, M. S., and Alexander, R.
W. (1994) J. Biol. Chem. 269, 32586-32591
35. Ogura, M., and Kitamura, M. (1998) J. Immunol. 161, 3569-3574
36. Hazzalin, C. A., Cano, E., Cuenda, A., Barratt, M. J., Cohen, P., and Mahadevan, L. C.
(1996) Curr. Biol. 6, 1028-1031
37. Kosugi, H., and Kikugawa, K. (1989) Free Radic. Biol. Med. 7, 205-207
38. Wu, D., and Cederbaum, A. I. (2003) J. Biol. Chem. 278, 1115-1124
39. Preville, X., Salvemini, F., Giraud, S., Chaufour, S., Paul, C., Stepien, G., Ursini, M. V.,
and Arrigo, A. P. (1999) Exp. Cell Res. 247, 61-78
40. Xu, J., Maki, D., and Stapleton, S. R. (2003) J. Biochem. Mol. Toxicol. 17, 67-75
41. Moriguchi, T., Kuroyanagi, N., Yamaguchi, K., Gotoh, Y., Irie, K., Kano, T., Shirakabe,
K., Muro, Y., Shibuya, H., Matsumoto, K., Nishida, E., and Hagiwara, M. (1996) J. Biol.
Chem. 271, 13675-13679
42. Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M.,
Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997) Science 275, 90-94
43. Kawaguchi, T., Osatomi, K., Yamashita, H., Kabashima, T., and Uyeda, K. (2002) J.
Biol. Chem. 277, 3829-3835
44. Suchankova, G., Tekle, M., Saha, A. K., Ruderman, N. B., Clarke, S. D., and Gettys, T.
W. (2005) Biochem. Biophys. Res. Commun. 326, 851-858
45. Lemieux, K., Konrad, D., Klip, A., and Marette, A. (2003) FASEB J. 17, 1658-1665
46. Pelletier, A., Joly, E., Prentki, M., and Coderre, L. (2005) Endocrinology 146, 2285-2294
47. Manning, B. D., and Cantley, L. C. (2003) Biochem. Soc. Trans. 31, 573-578
48. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H.,
Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., Gout, I., Downes, C. P., and Lamb,
R. F. (2004) J. Cell Biol. 166, 213-223
49. Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K.,
Cushman, S. W., Cooney, G. J., Atcheson, B., White, M. F., Kraegen, E. W., and
Shulman, G. I. (2002) J. Biol. Chem. 277, 50230-50236
50. Blaustein, M., Pelisch, F., Coso, O. A., Bissell, M. J., Kornblihtt, A. R., and Srebrow, A.
(2004) J. Biol. Chem. 279, 21029-21037
51. Patel, N. A., Chalfant, C. E., Watson, J. E., Wyatt, J. R., Dean, N. M., Eichler, D. C., and
Cooper, D. R. (2001) J. Biol. Chem. 276, 22648-22654
66
52. Patel, N. A., Kaneko, S., Apostolatos, H. S., Bae, S. S., Watson, J. E., Davidowitz, K.,
Chappell, D. S., Birnbaum, M. J., Cheng, J. Q., and Cooper, D. R. (2005) J. Biol. Chem.
280, 14302-14309
53. Weg-Remers, S., Ponta, H., Herrlich, P., and Konig, H. (2001) EMBO J. 20, 4194-4203
54. van der Houven van Oordt, W., Diaz-Meco, M. T., Lozano, J., Krainer, A. R., Moscat, J.,
and Caceres, J. F. (2000) J. Cell Biol. 149, 307-316
FOOTNOTES
*We thank Stacie Brower for experimental advice; Valerie Walker, Daniel Flynn, and Zhungxion
Tao for help with the PI3-kinase assays; and Brian Griffith and Callee McConnell for critical
reviews of the manuscript.  This work was supported by National Institutes of Health Grant
DK46897 to L.M.S.
1The abbreviations used are:  G6PD, glucose-6-phosphate dehydrogenase; IRS, insulin receptor
substrate; PI3-kinase, phosphoinositol-3 kinase; MAP, mitogen activated protein; p38 MAPK,
p38 mitogen activated protein kinase; ERK, extracellular regulated kinase; JNK, c-Jun amino-
terminal kinase; TNFa, tumor necrosis factor a; S6K1, S6 kinase 1; AMPK, AMP activated
protein kinase
2Talukdar, I. and Salati, L.M., unpublished observations
FIGURE LEGENDS
Fig. 1.  Arachidonic acid inhibits the insulin-mediated induction of G6PD mRNA in
primary rat hepatocytes.  Rat hepatocytes were plated onto collagen coated tissue culture dishes
in Hi/Wo/Ba medium plus 5% newborn calf serum.  After 3 to 4 h, the medium was changed to
serum-free medium and after 10 h Matrigel“ was added.  Twenty-four hours post isolation, the
cells (3 plates per treatment) were treated with or without 0.04 mM insulin ± 175 mM arachidonic
acid or with arachidonic acid alone.  After 24 h of treatment, the cells were harvested and total
RNA was isolated.  The top panel is a representative RNase protection assay.  The lower panel is
the results of two experiments (separate hepatocyte isolations) quantified using phosphorimaging
and ImageQuant software.  G6PD mRNA was normalized to the amount of b-actin mRNA and
the results are expressed relative to the amount of mRNA in no addition.  NA, no addition; FA,
arachidonic acid; Ins, insulin
Fig. 2.  Arachidonic acid inhibits Akt-activation and induces Ser307 phosphorylation of IRS-
1. Hepatocytes were treated with or without arachidonic acid (175 mM), 24h prior to the addition
of insulin (0.04 mM) and isolated 5, 10, 30 or 60 min after the addition of insulin.  (A) Western
blot analysis was performed against total and phosphorylated IRS-1 and Akt.  The antibodies
specifically detected IRS-1 phosphorylated at Ser307 or Ser612 and Akt phosphorylated at Ser473.
*The asterisk denotes a nonspecific band detected with the IRS-1 Ser307 antibody.  (B) The
amount of phosphorylated Akt in n=4 experiments for the 5, 10, and 30 min time points, and n=3
experiments for the 60 min.  Each bar is the mean ± SE for the indicated number of experiments
and the values are expressed as the fold increase in phosphorylated Akt relative to the amount in
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hepatocytes not treated with insulin or arachidonic acid.  (C) The amount of phosphorylated IRS-
1 (Ser307) for n=4 experiments for the 5, 10, and 30 min time points, and n=2 experiments for 60
min.  The values are expressed relative to the amount of phosphorylated protein in hepatocytes
not treated with insulin or arachidonic acid.  P-Akt, phosphorylated Akt; P-IRS-1, phosphorylated
IRS-1; FA, arachidonic acid; I, insulin.
Fig. 3.  Arachidonic acid activates p38 MAPK.  Hepatocytes were isolated and plated as
described in Fig. 1. Cell lysates was prepared after 2, 5, 10, 30, and 60 min from the untreated,
insulin (0.04 µM) treated or insulin + arachidonic acid (175 µM) treated cells.  (A) Western blot
analysis was performed against the phosphorylated and total forms of Erk, JNK and p38 MAP
kinases.  The antibodies for the phosphorylated MAP kinases recognize phosphates at Tyr183/185,
Thr183/Tyr185, and Thr180/Tyr182, respectively.  A representative blot of at least 4 separate
experiments is shown.  (B) Quantitative representation of the fold induction of phosphorylated
p38 MAPK in hepatocytes treated with insulin alone or insulin + arachidonic acid.  Each bar
represents the mean ± SE and the values are expressed relative to the absence of treatment.
Repetition was as follows:  n=4 for 2 min, n=6 for 5 min, n=8 for 10 min, n=4 for 30 min and n=2
for 60 min.  (C) Hepatocytes were incubated with insulin (0.4 µM) alone, arachidonic acid (175
µM) alone or insulin + arachidonic acid.  Cell lysates were prepared 5, 10, or 30 min later and
western blot analysis was performed against phosphorylated and total p38 MAPK.  The blot is
representative of n=3 separate experiments.  FA, arachidonic acid; P-p38, phosphorylated p38; P-
Erk, phosphorylated Erk; P-JNK, phosphorylated JNK; I, insulin.
Fig. 4.  A p38 MAPK inhibitor, SB203580, reverses the arachidonic acid-mediated decrease
of G6PD mRNA.  Hepatocytes were treated with or without 10 mM SB203580 for 1 h.  After 1 h
arachidonic acid (175 µM) was added, and 2 h later insulin (0.04 µM) was added.  After 12 h, the
medium was replenished with one of the same composition.  Total RNA was isolated after 24 h
with insulin.  The isolated RNA was analyzed by RNase protection assay and quantified using
phosphorimaging and ImageQuant software.  The values are the amount of G6PD mRNA
normalized to the amount of b-actin mRNA and are plotted relative to the amount of RNA in the
absence of treatments or inhibitor.  Each bar represents the mean ± SE of n=3 experiments.  I,
insulin; FA, arachidonic acid.
Fig. 5.  Inhibition of p38 MAPK blocks the decrease in Akt activation and the increase in
IRS-1 Ser307 phosphorylation by arachidonic acid.  Hepatocytes were treated with or without
arachidonic acid (175 mM) for 23 h. Cells were then incubated with or without 10 mM SB203580
for 1h, prior to the addition of insulin (0.04 µM).  Total cell lysates were isolated 5 min after the
addition of insulin. Western blot analysis was performed with antibodies against total and
phosphorylated Akt and IRS-1.  The antibody for phosphorylated IRS-1 recognizes phosphate at
Ser307 and the antibody for phosphorylated Akt recognizes phosphate at Ser473.  FA, arachidonic
acid; P-IRS-1, phosphorylated IRS-1; P-Akt, phosphorylated Akt.
Fig. 6.  TNFa inhibits activation of Akt, activates p38 MAPK and inhibits induction of
G6PD mRNA expression by insulin.  (A) Hepatocytes were treated with or without insulin
(0.04 mM) in the presence or absence of TNFa (10 ng/ml).  Total cell lysates were isolated 5, 10,
and 30 min after the addition of the treatments. Western blot analysis was performed against the
phosphorylated and total forms of Erk, JNK and p38 MAP kinases.  The antibodies for the
phosphorylated MAP kinases recognize phosphates at Tyr183/185, Thr183/Tyr185, and Thr180/Tyr182,
respectively.  (B) Hepatocytes were incubated with or without TNFa (10 ng/ml) for 24 h prior to
the addition of insulin (0.04 mM). Total cell lysates were isolated 5, 10, and 30 min following the
addition of insulin.  Western blot analysis was performed with the antibody against the
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phosphorylated Akt (Ser473).  The 5 min samples were from the same experiment but on a
separate gel from the other time points and were exposed on the same film.  (C) Hepatocytes were
treated with or without insulin (0.04 mM) and TNFa (10 ng/ml) as shown.  After 24 h, total RNA
was isolated and the amounts of G6PD and b-actin mRNA were measured by RNase protection
assay and imaged used phosphorimaging.  All of figures are representative blots of n=3
experiments.  FA, arachidonic acid; P-Akt, phosphorylated Akt; P-p38, phosphorylated p38; P-
Erk, phosphorylated Erk; P-JNK, phosphorylated JNK.
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Table 1.  Effect of various polyunsaturated fatty acids on Akt and p38 MAPK
phosphorylation.  Rat hepatocytes were either preincubated with fatty acid for 24 h prior to the
addition of insulin (Akt-phosphorylation), or treated simultaneously with insulin and 175 µM
fatty acid (p38 MAPK phosphorylation).  Total cell lysates were prepared 10 and 30 min after the
addition of insulin.  Total and phosphorylated Akt and p38 MAPK were determined by Western
blot analysis.  The values are the ratio of phosphorylated to total Akt or p38 MAPK and are
expressed relative to insulin alone.  The data are representative of n=2 experiments that showed
the same results.  18:2, linoleic acid; 18:3, linolenic acid; 20:5, eicosapentanoic acid; P-Akt,
phosphorylated Akt; P-p38, phosphorylated p38
Treatments P-Akt/Akt P-p38/p38
10 minutes
Insulin 100 1
Insulin + 18:2 52 2.3
Insulin + 18:3 33 1.6
Insulin + 20:5 26 11.1
30 minutes
Insulin 100 1
Insulin + 18:2 82 6
Insulin + 18:3 36 18
Insulin + 20:5 11 35
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Chapter 3
Title: Involvement of AMP-activated protein kinase (AMPK) in arachidonic acid-
mediated inhibition of G6PD mRNA expression.
Introduction:
Glucose-6-phosphate dehydrogenase (G6PD) is the first and the rate-limiting
enzyme in the pentose phosphate pathway. It converts glucose-6-phosphate into 6-
phospho-gluconate and as a byproduct it produces NADPH, a necessary component for
fatty acid biosynthesis. Thus, G6PD is known as a lipogenic enzyme.
Like other lipogenic enzymes, G6PD is regulated by hormonal factors and
nutritional status. Starvation of intact animals causes a decrease in G6PD expression
levels in liver, whereas refeeding a high carbohydrate diet induces this gene’s expression.
A low-fat diet (1% safflower oil to prevent essential fatty acid deficiency) induces G6PD
expression, while a high-fat diet (6% safflower oil) inhibits the expression level (1,2). In
parallel to the observation in intact animals, incubation of rat hepatocytes with insulin
induces G6PD expression several fold, whereas, addition of polyunsaturated fatty acids
like arachidonic acid reduces this expression by about 50% or more (2,3). Regulation of
G6PD expression both by high-fat diets in intact animals and by arachidonic acid in rat
hepatocytes takes place at a posttranscriptional level (1,2,4).
In our earlier work, we demonstrated that arachidonic acid-mediated inhibition of
G6PD mRNA expression involves the activation of the p38 mitogen activated protein
kinase (p38 MAP kinase) pathway (5). Activation of this pathway inhibits activation of
PI3 kinase in rat hepatocytes, and thereby the insulin-mediated induction of G6PD
mRNA (5,6). The mechanism by which the p38 MAP kinase pathway is turned on by
arachidonic acid is not known. AMP-activated protein kinase (AMPK), protein kinase C
(PKC) or mammalian target of rapamycin (mTOR) pathways have been demonstrated to
be activated by high-fat diet or free fatty acids, which in turn can interfere with the PI3
kinase pathway directly or via activation of MAP kinases.
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AMPK is activated by AMP in three different ways: by allosteric activation of
AMPK complex formation, by promoting phosphorylation at Thr-172 residue of AMPK
at the kinase domain, or by inhibiting dephosphorylation of Thr-172 via protein
phosphatase 2C (PP2C) (7). AMPK is activated by dietary polyunsaturated fatty acids in
intact animals (8). Activation of AMPK is necessary for the inhibition of lipogenic genes
in primary rat hepatocytes (9,10). Carbohydrate refeeding of starved animals decreases
hepatic AMPK activity, which leads to an activation of lipogenic gene expression (11).
Activation of AMPK can lead to the activation of p38 MAP kinase in ischemic heart (12),
and a commercially available activator of AMPK, 5-aminoimidazole-4-carboxamide
riboside (AICAR) is also capable of activating p38 MAP kinase in skeletal muscle and in
jejunum (13,14). As AMPK and G6PD are regulated by a similar dietary paradigm and
activation of AMPK can lead to the activation of p38 MAP kinase, AMPK seems to be a
strong candidate as a mediator for the arachidonic acid effect on G6PD.
Activation of PKC and/or mTOR pathways are the other potential mechanisms for
G6PD inhibition by arachidonic acid. Free fatty acids can activate various isoforms of
(PKC) and the activation of PKC can activate MAP kinases leading to insulin resistance
(15-18). High-fat diets containing 40% or more fat content inhibit the PI3 kinase pathway
by inducing Ser-307 phosphorylation of the insulin receptor substrate-1 (IRS-1).
Activation of mTOR and subsequent activation of p70 S6 kinase-1 (S6K-1) by high-fat
diets has been shown to be involved in this inhibitory mechanism (19-21). We
investigated the possibility of involvement of all these pathways in arachidonic acid-
mediated inhibition of G6PD expression either directly or by activating the p38 MAP
kinase pathway.
In this report we demonstrate that arachidonic acid activates AMPK in primary rat
hepatocytes. Activators of AMPK inhibit the insulin-mediated induction of G6PD gene
expression, thus mimicking the effect of arachidonic acid. AICAR inhibits the G6PD
gene expression by activating the p38 MAP kinase pathway and at the same time,
AICAR inhibits the PI3 kinase pathway, which is necessary for the insulin-mediated
induction of G6PD. Neither the PKC nor mTOR pathways are activated to contribute to
the inhibitory effect of arachidonic acid on G6PD gene expression.
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Materials and Methods:
Animal Care and Cell Culture- Male Sprague-Dawley rats (175-225 g) fed a standard
chow diet (Harlan Teklad) were used for all experiments. After a 16h starvation,
hepatocytes were isolated by collagen perfusion as previously described (2). Hepatocytes
(3.1 x 106) were plated onto rat-tail collagen coated dishes (60 mm) in Hi/Wo/Ba medium
(Waymouth's MB752/1 from Sigma, plus 20!mM HEPES, pH 7.4,!0.5!mM serine,
0.5!mM alanine, 0.2% bovine serum albumin) plus 5% newborn calf serum at 37°C and
with 5% CO2 as growth conditions. Cell viability in all experiments was 90% or greater
as estimated by trypan blue (0.04%) exclusion. Three to four hours after plating, the
medium was replaced with serum-free medium and a Matrigel overlay (0.3!mg/ml) was
added 4-5 h later. Twenty-four hours after the original plating, the medium was replaced
with one containing the treatments indicated in the figure legends. Subsequently, the
medium was replaced every 12-24 h with one of the same composition. Arachidonic acid
(Nu-Check Prep) was bound to bovine serum albumin (22) at the ratio of 4:1. The fatty
acid stocks contained butylated hydroxytoluene (0.01%), and the medium contained a-
tocopherol phosphate, disodium (10!µg/liter), to minimize oxidation of the fatty acids.
The AMPK activator, AICAR was purchased from Toronto Research Chemicals Inc. and
metformin was purchased from Sigma. The p38 MAP kinase inhibitor, SB203580 and the
mTOR pathway inhibitor, rapamycin, were purchased from Calbiochem. The PKC
inhibitor bisindolylmaleimide (GF-109203X) was purchased from Alexis Biochemicals,
the PKC activator, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), was purchased from
Sigma.
Isolation of Total RNA and mRNA measurement- Total RNA from 2-3 plates per
treatment was isolated by the method of Chomczynski and Sacchi (23). Determination of
the expression of RNA was performed using RNase protection assay (Ambion, Inc.) or
real-time reverse transcriptase polymerase chain reaction (RT-PCR). G6PD mRNA was
measured using RNase protection assays with a rat exon 13!template (24). A template for
rat b-actin was purchased from Ambion, Inc. The templates were linearized before use in
79
the in vitro transcription reaction. The probe and RNA were hybridized at 45!°C
overnight, and RNase digestion was done as previously described (4). Following
separation of the RNase-protected products in a 5% denaturing polyacrylamide gel, the
images were visualized using storage phosphor technology and quantified using
ImageQuant software by Amersham Biosciences.
Real-time RT-PCR assays using TaqMan probes were carried out in 96-well
plates using the QuantiTect probe RT-PCR kit (Qiagen). The reaction mixture per well
contained 10 µl of 2X QuantiTect RT-PCR Master Mix, 0.2 µl of QuantiTect probe RT
mix, 1 µl of 10 mM forward primer, 1 µl of 10 mM reverse primer, 1 µl of 10 mM
fluorogenic dual- labeled G6PD or RPL32 probe (6-FAM), and 200 ng of total RNA to a
total volume of 20 µl. Thermo-cycling conditions were as follows: 45 min at 50 °C for
reverse transcription; 15 min at 95 °C to activate DNA polymerase and to deactivate
reverse transcriptase; 35 cycles of 15 s at 94 °C to denature and 1 min at 56 °C to anneal
and extend. Reverse transcription and PCR amplification were performed by using
iCycler thermal cycler (Bio-Rad).
Preparation of Cell Extract and Western Blot Analysis-Hepatocytes were scraped using
350 ml of cell-harvesting buffer (10mM Tris, pH 7.4, 1% SDS) and the cell lysate was
sonicated and centrifuged at 14,000 rpm for 10 min. An aliquot of the supernatant was
used for protein quantification using the Bradford (Bio-Rad) assay. Following separation
by size on a 7.5% polyacrylamide gel, the proteins (20-40 mg in each lane) were
transferred to Immun-BlotTM polyvinylidene difluoride membrane (Bio-Rad) at 100V
for 1.5h in transfer buffer (25 mM Tris, 200 mM Glycine, 10% methanol). The
membranes were blocked with 5% nonfat dry milk in 1X TBS/0.05% Tween-20 buffer
for 1h and incubated with primary antibody diluted in 5% bovine serum albumin
overnight at 4 °C. The primary antibodies against phosphorylated Akt (Ser473),
phosphorylated IRS-1 (Ser307), phosphorylated p38 MAPK (Thr180/Tyr182),
phosphorylated AMPK (Thr172), phosphorylated acetyl-CoA-carboxylase (ACC, Ser79),
phosphorylated PKC (pan, bII Ser660), phosphorylated S6K-1, (Thr389), phosphorylated
MAP kinase kinase (MKK) 3/6 and total Akt, IRS-1, p38 MAPK, AMPK, ACC were
obtained from Cell Signaling Technology. Anti-rabbit IgG conjugated with horseradish
80
peroxidase (Cell Signaling Technology) was used as the secondary antibody, and the
immunocomplexes were detected by enhanced chemiluminescence (Pierce). Images were
visualized with film (Pierce) and quantified by densitometry using ImageQuant software
(Amersham Biosciences).
Results:
Arachidonic acid activates AMPK: Previous work has demonstrated that the inhibition of
lipogenic gene (for example acetyl-CoA- carboxylase, (ACC), fatty acid synthase (FAS),
and spot 14 expression by polyunsaturated fatty acids involves the activation of hepatic
AMPK in rat (8-10). These genes are regulated primarily by a change in the rate of
transcription. We asked if regulation of G6PD expression, which is exclusively
posttranscriptional, shared this signal transduction pathway. We first determined if
arachidonic acid activates AMPK in our primary rat hepatocyte culture. Phosphorylation
of AMPK, at Thr-172, gives a measure of the activated form of AMPK (25). Incubation
of hepatocytes with arachidonic acid induced AMPK-phosphorylation at Thr-172 as
compared to no treated or the insulin treatment alone, whereas total AMPK levels did not
change (Fig. 1). This activation of AMPK was rapid and was detected as early as 10 min
and retained through 60 min (data not shown). AMPK activation leads to Ser-79
phosphorylation of ACC protein (26). Phosphorylation of ACC at this site specifically
takes place by activated AMPK (26,27). We used phosphorylation of ACC as a control
for functional AMPK activation. ACC-phosphorylation at Ser-79 was highly induced
over no treatment or insulin treatment alone, indicating that arachidonic acid indeed
activates AMPK in rat hepatocytes. A decrease in total ACC was consistently observed in
cells incubated with fatty acids; the reason for this is not clear. Fatty acids are allosteric
inhibitors of ACC activity and are associated with the structural transition of the protein
from a polymeric to a protomeric form (28,29). Either of these effects may result in a
decrease in recognition of ACC by the antibody.
Previous data from our laboratory demonstrated that arachidonic acid activated
p38 MAP kinase and the activation was involved in the inhibition of G6PD expression
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(5). Coincident with the activation of AMPK, p38 MAP kinase was activated as
evidenced by the phosphorylation of p38 (Fig. 1). In addition, activation of p38 MAP
kinase was also accompanied by activation of MKK 3/6 (Fig. 1), which is a MAP kinase
kinase immediately upstream of p38 MAP kinase and is responsible for its
phosphorylation and activation. The coincident activation of these signaling molecules
and resultant inhibition of G6PD mRNA accumulation (data not shown) supports the
hypothesis that these pathways may be interrelated.
Activators of AMPK inhibit insulin-mediated induction of G6PD mRNA: We next wanted
to test if the activation of AMPK causes an inhibition of G6PD mRNA induction. A
known activator of AMPK, AICAR, was used to test if it can mimic the effect of
arachidonic acid on G6PD mRNA expression. AICAR, a widely used activator of AMPK
is a cell permeable adenosine analogue that can be phosphorylated to ZMP, an AMP
analogue and a known activator of AMPK (30). Insulin induced G6PD mRNA five fold
over no treatment; however, addition of AICAR in the medium inhibited this induction of
G6PD mRNA by 50% (Fig. 2). This mimics the extent of inhibition of G6PD mRNA by
arachidonic acid (5). We also used another known activator of AMPK, metformin (1
mM) to test if it can also inhibit G6PD expression. Metformin is a well-known drug for
type 2 diabetes and is an AMPK activator; however, the exact mechanism of activation of
AMPK by metformin is not known (31). Like AICAR, metformin also inhibited the
insulin-induction of G6PD mRNA by 50% or more (data not shown). From these data we
conclude that activators of AMPK can mimic the effect of arachidonic acid on the
expression of G6PD mRNA.
AICAR mediated inhibition of G6PD mRNA induction involves p38 MAP kinase pathway:
From the data obtained thus far, we hypothesized that activation of AMPK by
arachidonic acid causes the inhibition of G6PD mRNA expression by activating p38
MAP kinase. To test our hypothesis, we first determined if activation of AMPK could
induce p38 MAP kinase phosphorylation in our system. As shown in figure 3, AICAR
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activates AMPK by phosphorylating it at Thr-172 and at the same time AICAR increases
p38 MAP kinase phosphorylation over insulin treatment alone. If this activation of p38
MAP kinase is involved in the inhibition of G6PD expression, then inhibition of p38
MAP kinase should block the effect of AICAR. This was indeed observed. Insulin
induced G6PD mRNA expression more than 3.2 fold in the presence of the p38 MAP
kinase inhibitor SB203580; however, the AICAR-mediated inhibition of the G6PD
mRNA expression was completely abolished (Fig. 4). Expression of RPL32 mRNA, a
control for specificity of the treatments did not change (data not shown). Thus, the
AICAR-mediated inhibition of G6PD mRNA expression involves the p38 MAP kinase
pathway.
AICAR induces Ser-307 phosphorylation of IRS-1 and abolishes Akt-phosphorylation
upon pre-incubation: In our previous studies we have established that arachidonic acid
activates the p38 MAP kinase pathway, which in turn induces Ser-307 phosphorylation of
IRS-1, that thereby down regulates insulin signal transduction (5). Since the data thus far
indicated that AICAR, like arachidonic acid, induced p38 MAP kinase phosphorylation
and p38 MAP kinase was involved in the inhibition of G6PD mRNA accumulation, we
wanted to test if AICAR, like arachidonic acid, could also inhibit the PI3 kinase pathway.
As shown in figure 5, pre-incubation with AICAR induced Ser-307 phosphorylation of
IRS-1. In addition, the insulin-mediated induction of Akt-phosphorylation was
completely abolished in the presence of AICAR. Total IRS-1 and Akt expression were
not changed by AICAR. These results suggest that like arachidonic acid, AICAR
interferes with the PI3 kinase pathway resulting in a decrease in the expression of G6PD
mRNA expression.
Arachidonic acid does not mediate its inhibitory effect on G6PD mRNA expression via
activation of PKC: Free fatty acids can activate PKC in skeletal muscle, which in turn
activates MAP kinases and is associated with insulin resistance (16). To test if activation
of PKC is involved in the inhibition of G6PD mRNA expression, we measured PKC
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phosphorylation using western blot analysis. Cells treated with arachidonic acid did not
increase the phosphorylation of PKC, over insulin treatment alone (Fig. 6A). The phorbol
ester, TPA, a known activator of PKC, enhanced phosphorylation of PKC indicating that
PKC can be activated in rat hepatocytes (Fig. 6A). We also tested if the activaton of PKC
can mimic the effect of arachidonic acid on G6PD mRNA. TPA, instead of inhibiting
G6PD mRNA expression, actually enhanced the expression of G6PD mRNA compared
to insulin treatment alone (Fig. 6B). Various isoforms of PKC are known to activate the
PI3 kinase pathway (32,33). Activation of PI3 kinase by TPA and insulin may be
responsible for the enhanced G6PD expression.
To further confirm that PKC was not mediating the effect of arachidonic acid, we
tested if a specific inhibitor of PKC, bisindolylmaleimide I, (GF-109203X) can reverse
the effect of arachidonic acid on G6PD gene expression (Fig. 6C). The PKC inhibitor
could not reverse the effect of arachidonic acid on G6PD mRNA expression. Thus, in
primary rat hepatocytes, PKC is not an intermediate in arachidonic acid inhibition of
G6PD expression.
Arachidonic acid-mediated inhibitory effect on G6PD mRNA does not involve the
activation of mTOR pathway: mTOR is a downstream effector protein of the PI3 kinase
pathway, activation of which leads to protein translation and cellular growth (34).
Insulin-mediated induction of Akt stimulates activation of this protein (35). Rapamycin
abolishes the activity mTOR by a mechanism yet to be discovered (34). Others (6) and
we (Fig. 7A) found that insulin-mediated induction of G6PD mRNA expression is
completely abolished when cells are treated with rapamycin. This suggests that activation
of mTOR by insulin is required for the insulin-mediated induction of G6PD mRNA
expression.
Prolonged and sustained activation of mTOR by feeding intact animals a very
high-fat diet inhibits insulin signal transduction and promotes insulin resistance (21).
Incubation of rat hepatocytes with low concentrations of arachidonic acid is not the same
as long term feeding a high-fat diet. None-the-less, we asked if mTOR was over activated
by arachidonic acid and if this activation was involved in inhibition of G6PD mRNA
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expression. Western blot analysis was performed against the phosphorylated/activated
form of a downstream effector protein of mTOR, p70 S6K-1. Insulin induces the
activation of p70 S6K-1 over no treatment (Fig 7C). Pre-incubation of hepatocytes with
arachidonic acid did not increase the phosphorylation of p70 S6K-1 over insulin
treatment alone instead, at 5 and 10 min, the phosphorylated form of p70 S6K-1 was
inhibited in the presence of arachidonic acid (Fig 7C). Activation of AMPK abolishes the
mTOR activity (36). We found the same when we treated cells with the AMPK activator
AICAR (Fig. 7B). We already have established that arachidonic acid activates AMPK in
primary rat hepatocytes. This data adds another indirect evidence to that observation.
From these experiments it was concluded that activation of mTOR by insulin is
required for the insulin-mediated induction of G6PD expression. Inhibition of that by
arachidonic acid, most likely via activation of AMPK, results in a decrease in mTOR/p70
S6K-1 activation. This is a probable cause of attenuation of insulin induction on G6PD
mRNA expression. From these results it was confirmed however, that neither PKC, nor
mTOR pathways are activated by arachidonic acid in our experimental condition, which
can attenuate insulin signal transduction and thus can inhibit insulin-induction on G6PD
mRNA expression.
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Discussion :
In our previous study, we have shown that arachidonic acid-mediated inhibition of
insulin-induced G6PD mRNA expression involves the activation of p38 MAP kinase
pathway, which in turn interferes with the PI3 kinase pathway by phosphorylating IRS-1
at Ser-307, thus inhibiting the insulin-mediated induction of G6PD (5). In this report we
have demonstrated that incubation with arachidonic acid results in activation of AMPK
(Fig. 1). We present the following lines of evidence that AMPK is a mediator in the
arachidonic acid inhibition of G6PD expression. First, activation of AMPK by other
agents, such as AICAR, concomitantly activates p38 MAP kinase and Ser-307
phosphorylation of IRS-1, inhibits AKT phosphorylation (Figs. 3 and 5 respectively) and
inhibits insulin-induced G6PD mRNA. Second, inhibition of p38 MAP kinase also blocks
the effect of AICAR on G6PD mRNA accumulation (Fig. 4). Third, these changes in the
activity of signaling pathways and G6PD expression occur within the same time frame as
arachidonic acid activation of AMPK and arachidonic acid inhibition of G6PD
expression. Our data do not support the notion of the activation of PKC or mTOR
pathways by arachidonic acid in our experimental condition and their involvement is
unlikely in the inhibition of insulin-induction on G6PD expression (Fig. 6 and 7). Thus,
our data are consistent with the hypothesis that activation of AMPK by arachidonic acid
enhances p38 MAP kinase activity resulting in the inhibition of insulin signal
transduction and thereby G6PD expression.
The activities of the lipogenic enzymes, including G6PD, are coordinately
regulated. In this regard, feeding a high-carbohydrate diet increases their activity and
starvation or feeding polyunsaturated fatty acids decreases their activity. Activation of
AMPK, which mediates the regulation of many of these lipogenic genes, is inversely
regulated under the same dietary paradigm (8-11). The details by which these lipogenic
genes are regulated have substantial differences. Those genes regulated by transcriptional
mechanisms use a different combination of the transcriptional factors (37) and G6PD
differs in that the regulation occurs by changes in the rate of mRNA splicing (1,4,24,38).
Yet it appears that the signaling pathways affecting these changes may have more in
common and AMPK may act as a common upstream signaling molecule that accounts for
the coordinate regulation of the lipogenic genes.
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High concentrations of dietary fat cause pathological conditions such as insulin
resistance, which leads to type 2 diabetes and obesity in intact animals. We, however, are
looking at the normal dietary regulation of a lipogenic gene involving low amounts of
dietary polyunsaturated fat (6% by weight). Dietary intake of high-fat (40% or more)
leads to the prolonged activation of mTOR pathway causing insulin resistance. In our
system, however, arachidonic acid fails to increase phosphorylation of S6K-1, and on the
contrary, it decreases phosphorylation of S6K-1 at earlier time points (Fig. 7C).
Activation of AMPK leads to down regulation of mTOR/S6K-1 pathway (7,34,39). A
decrease in S6K-1 phosphorylation upon arachidonic acid treatment thus, indirectly
provides another line of evidence of activation of AMPK by arachidonic acid in our
system. Rapamycin, the inhibitor of mTOR abolishes the insulin-mediated induction of
G6PD mRNA (Fig. 7A), (6), which suggests that basal level activation of mTOR by
insulin, a downstream effector protein of PI3 kinase, is required to mediate the insulin
induction on G6PD mRNA. Activation of AMPK by arachidonic acid is the most logical
reason for the decrease in the mTOR/S6K-1 pathway. This suggests that arachidonic acid
not only attenuates the activation PI3 kinase but also decreases the insulin-mediated basal
level activation of mTOR by activating AMPK to prevent the insulin-mediated induction
of G6PD mRNA expression.
G6PD is regulated at the level of splicing by polyunsaturated fatty acids.
Unpublished data from our laboratory indicates the involvement of various splicing co-
activators/repressors in this mechanism. Nuclear localization as well as the post-
translational modifications such as phosphorylation/dephosphorylation status of these
splicing factors is important for their activity (40-44). Various reports have demonstrated
the involvement of the PI3 kinase as well as various MAP kinase pathways in this regard
(45-49). How the activation of AMPK/p38 MAP kinase pathway by arachidonic acid
ultimately transduces the signal at the level of splicing of G6PD mRNA in the nucleus is
currently under investigation.
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Figure Legends:
Figure 1.  Arachidonic acid induces activation of AMPK. Rat hepatocytes were plated
onto collagen coated plates in Hi/Wo/Ba medium plus 5% newborn calf serum. After 3 to
4h, the medium was changed to serum free medium and after 10h, matrigel ® was added.
Twenty-four hours post-isolation, the cells (2 plates per treatment) were treated with
insulin (0.04 mM) alone or insulin in the presence of arachidonic acid (175 mM) or left
untreated. Total cell lysates were isolated 10 min after the treatments. Western blot
analysis was performed against phosphorylated AMPK at Thr-172 and total AMPK,
phosphorylated ACC at Ser-79, and total ACC, phosphorylated MKK 3/6, and
phosphorylated (Thr 180/Tyr 182) and total p38 MAP kinase. A representative blot is
shown. Repetition was as follows: n=3 experiments for phosphorylated and total AMPK
and ACC, n=2 for P-MKK 3/6, n=7 for phosphorylated and total p38 MAP kinase. P-
AMPK, phosphorylated AMPK, P-ACC, phosphorylated ACC, P-MKK 3/6,
phosphorylated MKK 3/6, P-p38, phosphorylated p38 MAP kinase, FA, arachidonic acid.
Figure 2.  Activators of AMPK inhibit insulin-mediated induction of G6PD mRNA.
Rat hepatocytes were treated with insulin (0.04 mM) alone or insulin in the presence of
AICAR (0.5 mM). The medium was changed every 12h of incubation with one of the
same composition and treatments. After 24h, total RNA was isolated. Real time RT-PCR
using a Taqman probe was used to measure the expression of G6PD mRNA. Quantitative
analysis of G6PD mRNA expression is shown for n=4 experiments. Each bar represents
the mean ± SE and the values are expressed relative to the absence of the treatment. NA,
no addition, I, insulin.
Figure 3.  AICAR increases phosphorylation of p38 MAP kinase. Rat hepatocytes
were treated with insulin (0.04 mM) alone or insulin in the presence of AICAR (0.5 mM)
for 10 minutes. Total cell lysates were isolated and western blot analysis was performed
against phosphorylated AMPK at Thr-172, and phosphorylated and total p38 MAP
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kinase. A representative blot is shown in the left panel. Quantitative analysis of the
amount of phosphorylated p38 is shown in the right panel for n=4 experiments. Each bar
represents the mean ± SE and the values are expressed relative to the absence of the
treatment. NA, no addition, I, insulin.
Figure 4.  AICAR mediated inhibition of G6PD mRNA induction involves the p38
MAP kinase pathway. Rat hepatocytes were incubated with 10 mM of the p38 MAP
kinase inhibitor SB203580 for 1h. The cells were then incubated with AICAR or left
untreated for an additional 2h. After pre-incubation with SB203580 and AICAR the cells
were treated with or without insulin (0.04 mM). Medium was changed every 12h to one of
the same composition of the inhibitor, AICAR and insulin. Total RNA was isolated 24h
after the addition of the insulin. Real time RT-PCR was performed to measure the
expression of G6PD mRNA. Quantitative analysis of G6PD mRNA expression is shown
for n=3 experiments. Each bar represents the mean ± SE and the values are expressed
relative to the presence of the inhibitor but absence of the treatments. SB, SB203580, NA,
no addition, I, insulin.
Figure 5.  AICAR induces Ser-307 phosphorylation of IRS-1 and abolishes Akt-
phosphorylation. Hepatocytes were treated with or without AICAR (0.5 mM) 24h prior
to the addition of insulin (0.04 mM). Total cell lysates were prepared 10 min after the
addition of insulin. Western blot analysis was performed against total and phosphorylated
IRS-1 and Akt. The antibodies specifically detected IRS-1 phosphorylated at Ser-307,
and Akt phosphorylated at Ser 473. A representative blot of n=4 experiments is shown.
NA, no addition, I, insulin, P-IRS-1, phosphorylated IRS-1, P-Akt, phosphorylated Akt.
Figure 6.  Arachidonic acid does not mediate its inhibitory effect on G6PD mRNA
via activation of PKC. (A) Rat hepatocytes were treated with insulin (0.04 mM) in the
presence or absence of arachidonic acid (175 mM) or an activator of PKC, TPA
(50ng/ml), or left untreated. Total cell lysates were isolated after 10 or 30 min of
incubation. Western blot analysis was performed against phosphorylated PKC. A
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representative blot of n=2 experiments is shown. (B) Rat hepatocytes were treated with or
without insulin (0.04 mM) in the absence or presence of TPA. Medium was changed after
12h, and after 24h, total RNA was isolated. The amount of G6PD mRNA expression was
measured by real time RT-PCR. Quantitative analysis of two experiments is shown.
Values are expressed relative to the absence of the treatments. (C) Hepatocytes were
treated with or without 1 or 5 mM of the PKC inhibitor, GF-109203X, 1h prior to the
addition of arachidonic acid (175 mM). Insulin (0,04 mM) was added 4h after the addition
of arachidonic acid. After 12h, the medium was changed with one of the same
composition of the inhibitor and the treatments. Total RNA was isolated after 24h. The
isolated RNA was analyzed by RNase protection assay and quantified using
phosphorimaging and ImageQuant software. The values are the amount of G6PD mRNA
normalized to the amount of b-actin mRNA and are plotted relative to the amount of
RNA in the absence of treatments or inhibitor. Each bar represents the mean ± SE of n=3
experiments for no addition and GF-109203X at 1 mM concentration, for GF-109203X at
5 mM concentration, average of n=2 experiments are shown. P-PKC, phosphorylated
PKC, NA, no addition, I, insulin, FA, arachidonic acid, GF 1, GF-109203X at 1 mM, GF
5, GF-109203X at 5 mM.
Figure 7.  Arachidonic acid-mediated inhibition of G6PD mRNA does not involve
the activation of mTOR pathway. (A) Hepatocytes were treated with or without 100
nM of rapamycin, 4 h prior to the addition of arachidonic acid (175 mM). Insulin (0.04
mM) was added 2 h after the addition of arachidonic acid. After 12 h, the medium was
changed with one of the same composition of the inhibitor and the treatments. Total RNA
was isolated after 24h. The isolated RNA was analyzed by RNase protection assay and
quantified using phosphorimaging and ImageQuant software. The values are the amount
of G6PD mRNA normalized to the amount of b-actin mRNA and are plotted relative to
the amount of RNA in the absence of treatments or inhibitor. Each bar represents the
mean ± SE of n=3 experiments. NA, no addition, I, insulin, FA, arachidonic acid. (B)
Hepatocytes were treated with or without AICAR (0.5 mM) either 24h prior to the
addition of insulin (0.04 mM) (lanes 1-3), or with insulin (lanes 4-6). Total cell lysates
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were prepared 20 min after the addition of insulin (for lanes 1-3) or the treatments (lanes
4-6). Western blot analysis was performed against phosphorylated-S6K-1. (C)
Hepatocytes were treated with or without 175 mM arachidonic acid 24h prior to the
addition of 0.04 mM insulin. Total cell lysates were isolated 5 or 10 min after the addition
of the insulin. Western blot analysis was performed against phosphorylated-S6K-1. P-
S6K-1, phosphorylated S6K-1, I, insulin, FA, arachidonic acid.
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Summary:
Based on the results in chapter 2 and 3, we have concluded that insulin-mediated
induction of G6PD follows the activation of the PI3 kinase pathway in primary rat
hepatocytes. Addition of arachidonic acid, a polyunsaturated fatty acid, in the medium
interferes with the PI3 kinase pathway, and thus inhibits the insulin-mediated induction
of G6PD. The findings from this study reveal that arachidonic acid in the presence of
insulin induces p38 MAP kinase pathway to a greater extent than insulin or arachidonic
acid treatments alone. This increase in induction of p38 MAP kinase interferes with the
insulin signal transduction pathway, by phosphorylating IRS-1 at Ser-307 and preventing
PI3 kinase activation and Akt-phosphorylation. Inhibition of the p38 MAP kinase
pathway by using a specific inhibitor, SB203580, attenuates the inhibitory effect of
arachidonic acid on G6PD and at the same time reverses its effect on IRS-1 and Akt-
phosphorylation. Other polyunsaturated fatty acids, linoleic, a-linolenic and
eicosapentanoic acids, also induce p38 MAP kinase, decrease Akt-phosphorylation and
prevent G6PD induction, eicosapentanoic acid being the most effective one. TNF-a, a
known inducer of p38 MAP kinase and an inhibitor of the PI3 kinase pathway, is capable
of reducing G6PD gene induction. This data together suggests that activation of p38
MAP kinase pathway is necessary if not sufficient, for the inhibition of G6PD mRNA
accumulation.
We also have studied the possible involvement of AMPK, PKC or mTOR
pathways in the regulation of G6PD by arachidonic acid. We found that arachidonic acid
activates AMPK by phosphorylating it at Thr-172. Activators of AMPK, AICAR and
metformin inhibit the induction of G6PD by insulin. This study also reveals that AICAR
induces p38 MAP kinase phosphorylation in primary rat hepatocytes and inhibition of
this induction abolishes the inhibitory effect of AICAR on G6PD. Addition of
arachidonic acid inhibits the phosphorylation of the downstream effector protein of
mTOR, S6K-1 at Thr-389. This provides indirect evidence of the activation of AMPK by
arachidonic acid, as activation of AMPK results in the inhibition of mTOR/S6K-1.
However, inhibition of mTOR, rather than activation, rules out the possibility of
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involvement of this pathway in the interference of the PI3 kinase activation upon
arachidonic acid treatment. We also have ruled out the possibility of involvement of
PKC, as neither activators of PKC mimic the action of arachidonic acid on G6PD nor
inhibitors of PKC can abolish the effect of arachidonic acid on G6PD gene expression.
This study provides a novel mechanism by which a polyunsaturated fatty acid-
signal is transduced in hepatocytes. While other lipogenic genes are regulated at the
transcriptional level, G6PD is unique in the sense that it is regulated at the level of
splicing by polyunsaturated fatty acids (Amir-Ahmady and Salati, 2001, Tao et al, 2002).
How the signal transduction cascade, which starts at the cell membrane, transduces its
signal to the event of splicing in the nucleus is largely unknown. Investigation from our
laboratory revealed the involvement of various splicing factors in the regulation of
splicing of G6PD (Griffith, B and Salati, LM, unpublished). Involvement of various
signal transduction pathways in the activation of these splicing factors has been reported
(Patel et al, 2001, Patel et al, 2003, Konig et al, 1998, van der Houven van Oordt et al,
2000, Weg-Remers et al, 2001). Establishment of a functional co-relation between the
signal transduction pathway, which starts with an AMPK/p38 MAP kinase activation by
arachidonic acid and eventually regulates splicing of G6PD is the future goal of this
study.
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Appendix:
In this section I am summarizing the results of the experiments, which could not be
inserted in chapters 2 or 3 but are relevant to those studies. Some preliminary
experiments, which are not related to those two chapters and are not making a complete
story, are also included in this section.
Figure A-1. A PI3kinase inhibitor LY294002 abolishes the insulin-mediated
induction of G6PD. Rat hepatocytes were incubated with 75 mM LY294004, 1 hr prior
to the addition of insulin (I) (0.04 mM) or insulin + arachidonic acid (175 mM) (I+FA).
The control group (No Addition) was treated with DMSO (solvent used for the inhibitor)
1 h prior to the addition of the treatments. After 12 h, culture medium was changed to one
of the same composition and after 24 h total RNA was isolated. RNase protection assay
was performed to determine the fold induction of G6PD expression. Expression of b-
actin was also determined from each sample as a negative control. The figure represents
n=4 experiments.
Results: The induction of G6PD mRNA by insulin occurs via the PI3-kinase signal
transduction pathway (Stapleton et al. J Biol. Chem, 1998, 273:14968-14974). We have
confirmed that an inhibitor of this pathway, (LY294002), abolishes the effect of insulin
on G6PD mRNA expression. As shown in figure A-1, pre-incubation of hepatocytes with
75 mM LY294002, 1 h prior to the addition of insulin abolishes the insulin-mediated
induction of G6PD mRNA. We have used different concentrations of the inhibitor and
found that the inhibitor has its maximum effect at 75 mM, which is maintained at 100 mM
(Data not shown). I, insulin, FA, arachidonic acid.
Figure A-2. An Erk MAP kinase inhibitor PD98059 has no effect on arachidonic
acid mediated inhibition of G6PD. Hepatocytes were incubated in the absence or
presence of 50 mM Erk MAP kinase inhibitor PD98059, when hepatocytes were treated
either with insulin (0.04 mM) +/- arachidonic acid (175 mM) or kept untreated. The
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inhibitor was added 1h prior to the addition of arachidonic acid. Insulin was added 3h
later. After 12h, medium was changed with medium containing the inhibitor and the
treatments together. After 24h total RNA was isolated. Quantitative analysis of fold
induction of G6PD in two experiments is shown in figure A-2. Values are normalized to
no treatment in the absence of the inhibitor.
Results: The Erk inhibitor seems to have no effect on the arachidonic acid-mediated
inhibition of G6PD. I, insulin, FA, arachidonic acid, PD, PD98059.
Figure A-3. Farnesyl transferase inhibitor B581 inhibits MKK 3/6 and p38
activation and also abolishes the effect of arachidonic acid on G6PD mRNA
expression; a possible role of Ras as an upstream effector protein. (A) Rat
hepatocytes were treated with or without 50 mM of B581 1h prior to the addition of
insulin (0.04 mM) in the absence or presence of arachidonic acid (175 mM) or left
untreated. After 10 min, a total cell lysate was isolated and western blot analysis was
performed against phosphorylated MKK3/6 and phosphorylated and total p38 MAP
kinase. A representative blot of n=2 experiments is shown. (B) Hepatocytes were treated
with or without 50 mM of B581 1h prior to the addition of arachidonic acid. After 4h,
insulin was added. After 12h, medium was changed with the same composition of the
inhibitor and the treatments. Total RNA was isolated after 24h. The isolated RNA was
analyzed by RNase protection assay and quantified using phosphorimaging and
ImageQuant software. The values are the amount of G6PD mRNA normalized to the
amount of b-actin mRNA and are plotted relative to the amount of RNA in the absence of
treatments in the absence or presence of the inhibitor. Each bar represents the mean ± SE
of n=6 experiments.
Results: We wanted to determine if B581 can abolish the arachidonic acid-mediated
activation of p38 MAP kinase and if it has any effect on G6PD mRNA expression by
arachidonic acid. Western blot analysis shows that B581 not only abolishes p38 MAP
kinase activation but also inhibits the upstream MKK3/6 phosphorylation. However, total
p38 MAP kinase expression did not change.
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We also tested if this inhibitor can abolish the effect of arachidonic acid on
G6PD. In the absence of the inhibitor, arachidonic acid inhibits insulin induction by 49 ±
4.5 %, whereas, in the presence of B581, the arachidonic acid-mediated inhibition is only
15 ± 5.4 % and this decrease is not significantly different from insulin + B581 treatment.
B581, however, did decrease the insulin-mediated induction of G6PD mRNA and this
decrease is statistically significant (P<0.05). In the absence of the inhibitor we see 4.8-
fold induction over no addition, which is reduced to 3-fold in the presence of the
inhibitor. This is probably due to the fact that Ras also contributes to the activation of the
PI3kinase pathway and the activation of this pathway is necessary for the activation of
G6PD mRNA. Inhibition of Ras-farnesylation can cause a decrease in the activation of
the PI3kinase, which in turn can decrease the extent of G6PD induction by insulin.
However, there is still 3-fold induction by insulin in the presence of the inhibitor which
arachidonic acid could not inhibit. This data suggests that inhibition of Ras-farnesylation
abolishes the inhibitory effect of arachidonic acid on G6PD mRNA expression. NA, no
addition, I, insulin, FA arachidonic acid.
Figure A-4. Effect of AMPK activators on G6PD, at an earlier time point (10h). Rat
hepatocytes were treated with insulin (0.04 mM) alone or insulin in the presence of
AICAR (0.5 mM), metformin (1 mM) or 2,4, DNP (0.1 mM). Total RNA was isolated
after 10h. Real time RT-PCR using Taqman probe was used to measure the expression of
G6PD mRNA. Quantitative analysis of G6PD mRNA expression is shown for n=1
experiment. Each bar represents the values relative to the absence of the treatment.
Results: Incubation of rat hepatocytes with AMPK activators for a shorter period of time
showed that, AICAR and 2,4 DNP inhibited the induction of G6PD mRNA to about 30%
and 50% respectively. AICAR mediated inhibition is greater at 24h time point (50%). On
the other hand, metformin, contrary to the later time point (24h) did not inhibit the insulin
induction.
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Figure A-5. Effect of various polyunsaturated fatty acids (PUFAs) on P-AMPK, P-
p38 and G6PD: A) Rat hepatocytes were incubated, with or without insulin (0.04 mM) in
the absence or presence of various PUFAs (175 mM). Total cell lysate was isolated after
10 min. Western blot analysis was performed against phospho and total AMPK and p38
MAP kinase. Quantitation of the P-AMPK (n=3 for all Fatty acids, except n=2 for 18:3)
and P-p38 (n=3 experiments) was performed using densitometric analysis and
ImageQuant software. Each bar represents the mean ± SE and the values are expressed
relative to the insulin treatment for P-AMPK and relative to the no addition for P-p38. B)
Rat hepatocytes were treated with or without insulin in the absence or presence of 175
mM of the designated PUFAs. After 12 h, the medium was changed. After 24 h, total
RNA was isolated and real time RTPCR was performed against G6PD and beta-actin (as
a control). Quantitative analysis of n=3 experiments are shown. Each bar represents the
mean ± SE and the values are expressed relative to the no addition sample.
Results: The result for P-AMPK suggests that insulin reduces AMPK phosphorylation
over no addition (NA). Upon treatment with 18:2 or 20:5 fatty acids, the P-AMPK values
are increased compared to insulin treatment alone. To conclude about the effect of 18:3,
more experiments are required since the values are variable. On the other hand, all these
fatty acids induce p38-phosphorylation with a maximum effect of 20:5. All these fatty
acids also reduce G6PD mRNA abundance with a maximum effect of 20:5.
Figure A-6. Effect of fibroblast growth factor 19 (FGF-19), and chenodeoxycholic
acid (CDCA) on G6PD mRNA level: Effect of FGF-19 and CDCA on G6PD were
examined in the presence of insulin and LXR agonist T0-901317 (T-17) (This was a
collaborative project with Sushant Bhatnagar in Dr. Brad Hillgartner’s lab). Hepatocytes
were incubated in the presence of insulin and T-17 (6.5 mg/ml) with or without FGF-19
(50 ng/ml), or CDCA (50 and 75 mM). Medium was changed after 12 h and total RNA
was isolated 24 h after the addition of the treatments. The isolated RNA was analyzed by
RNase protection assay and quantified using phosphorimaging and ImageQuant software.
The value of n=1 experiment is shown. The amount of G6PD mRNA was normalized to
the amount of b-actin mRNA and plotted relative to the amount of RNA in the presence
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of insulin and T-17. The blank lane where the sample was lost during the assay contained
500 ng/ml FGF-19 in the presence of insulin and T17.
Results: From the preliminary experiment it seems that both FGF-19 and CDCA, two
known potent inhibitors of lipogenic genes, also inhibit the expression of G6PD in the
presence of insulin and T-17.
Figure A-7. Effect of insulin and arachidonic acid on the splicing of rat G6PD
mRNA. In order to determine how insulin and arachidonic acid affect the splicing of rat
G6PD mRNA (all work on the splicing of G6PD was done before with mouse G6PD
gene either from intact animals or from transiently transfected mouse G6PD reporter
RNA into rat hepatocytes), nuclear RNA was isolated from rat hepatocytes treated with
insulin in the absence or presence of arachidonic acid or from the untreated group. After
12h of treatment, the medium was changed and after 24h nuclear RNA was isolated from
12-15 plates per treatment group. We already have shown that the regulatory element of
mouse G6PD gene is located within exon 12. Thus, we performed RNase protection
assay with a probe, spanning rat G6PD exons 10-12 and the intervening introns (pAB2).
A) The cartoon shows the diagram and size of the full-length, partially-spliced and fully-
spliced probe. The unspliced probe is 364 nucleotides (nt). The predicted size of the two
partially spliced products containing exon 11, intron 11 and exon 12 or exon 10, intron 10
and exon 11 are 234 and 207 nt, respectively. The fully spliced products should be 77
(exon 11), 60 (exon 12) and 22 (exon 10) nt. B) A representative RNase protection assay
gel is shown. From the gel we were able to detect the unspliced, the partially spliced
(containing exon 10, intron 10 and exon 11) and the fully spliced (containing exon 11)
probes. The quantitation of these products was done using ImageQuant software. The
value of each band for the I+FA treatment as a percentage of insulin treatment alone is
shown for n=4 individual experiments. The unspliced probe was not detectable in two
experiments.
Results: The result is largely inconclusive at this moment except that the percent
expression of the fully spliced product in the presence of arachidonic acid is always less
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than the partially spliced or the unspliced probe. This might suggest an involvement post-
transcriptional mechanism by arachidonic acid for rat G6PD gene expression.
Figure A-8. Stable transfection of the construct containing mouse exon 7-13 into the
L6 cell line. Stable transfection of the mouse G6PD gene construct containing exon 7-13
and driven by a CMV promoter was performed in rat L6 cell line by Effectene
transfection reagent. After clonal isolation, real time RT-PCR was performed to detect
mouse G6PD in these cells. Agarose gel was run with the PCR products. As shown all the
clones are expressing mouse G6PD construct.
Figure A-9A. Effect of arachidonic acid, the PI3 kinase inhibitor LY294002 and the
p38 MAP kinase inhibitor, SB203580 on steroyl-coA-desaturase (SCD) gene
expression A) Primary rat hepatocytes were incubated with 75 or 100 mM LY294004
(LY 75 and LY100 respectively), 1 hr prior to the addition of insulin, or insulin +
arachidonic acid. The control group was treated with DMSO (solvent used for the
inhibitor) 1 h prior to the addition of the treatments (Experiment # 3). In two other
experiments hepatocytes were treated either with insulin or arachidonic acid alone or with
both (Experiment # 1 and 2). After 12 h, culture medium was changed to one of the same
composition and after 24 h total RNA was isolated. Northern blot analysis was performed
to determine the fold induction of SCD expression. The values are the amount of SCD
mRNA plotted relative to the amount of RNA in the absence of treatments and in the
absence or presence of the inhibitor. The picture of 18S and 28S rRNA is shown as a
loading control. B) Rat hepatocytes were incubated with or without 10 mM of p38 MAP
kinase inhibitor SB203580. After 1h, cells were treated with arachidonic acid or left
untreated. 2 h after that cells were treated with or without insulin. Medium was changed
after 12h with the same composition of the inhibitor, arachidonic acid and insulin. Total
RNA was isolated 24h after the addition of the treatment. Northern blot analysis was
performed to measure the expression of SCD mRNA. Percentage of inhibition of SCD
gene expression by arachidonic acid in the absence or presence of SB203580 compared
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to insulin treatment alone is shown for two separate experiments. The picture of 18S and
28S rRNA is shown as a loading control.
Results: A) Insulin induces SCD several fold. Arachidonic acid reduces the expression of
both the basal and the insulin-induced expression of SCD. The insulin-mediated
induction of SCD is completely abolished by the PI3kinase inhibitor LY294002 at both
75 and 100 mM concentrations. B) The p38 MAP kinase inhibitor SB203580 slightly
reduces the % of inhibition of the SCD gene expression by arachidonic acid.
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